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Abstract 
Jembrana disease virus  (JDV) is a bovine lentivirus that causes  an acute severe 
disease syndrome in banteng cattle (Bos javanicus) in Indonesia. In order to develop a 
vaccine, JDV capsid (CA) protein together with transactivator of transcription (Tat) 
have been produced and expressed in a microbial system with limited success, but 
surface  unit  glycoprotein (SU) is difficult to produce in E.coli  as it requires 
glycosylation and post-translational modification. In an approach to overcome the 
limitations of a microbial antigen expression system, in this study, JDV fused CA-Tat 
and SU regions were introduced into tobacco plants and analysed for protein 
expression. 
Plants have considerable potential for the production of biopharmaceutical proteins 
and peptides because they are readily  transformed and can provide a cheap and 
reliable source of recombinant proteins. The protein synthesis pathway is highly 
conserved between plants and animals. Plant-derived biopharmaceuticals can also be 
scaled up for mass production, and are potentially safer, that is, they are not liable to 
be contaminated by mammalian viruses compared with products derived from 
animals or animal cell lines. The overall benefits are the range  of recombinant 
proteins that can be produced in plants and the flexibility that is allowed in the 
engineering of new pharmaceutical proteins, which can be designed with plant 
expression in mind. 
The aim of this work was to use transgenic tobacco lines as a system for production 
of recombinant antigens for JDV. CA-Tat and SU region of JDV genome were iv 
 
successfully cloned into the plant transformation vector and introduced into tobacco 
(Nicotiana tabacum) using Agrobacterium mediated plant transformation. Transgenic 
plants (T0 and T1) were successfully generated. A total of 12 T0 plant for CA-Tat and 
21 for SU were obtained. Transgenic tobacco plants (T1
Another objective undertaken in parallel with this work was to study the potential of 
porcine circovirus (PCV) rep gene promoter to act as a novel promoter in plants, and 
which could provide freedom to operate. To achieve this aim, an expression construct 
was created containing the PCV promoter in frame with a gus  gene, and 9 
transformed tobacco lines (T
) were examined by PCR, 
SDS/PAGE, western blotting, dot-blot and semi-quantitative reverse transcriptase 
(RT) PCR. RT-PCR analysis confirmed the presence of mRNA of the inserted gene 
in all the transgenic plant lines tested. However, using western blotting and Dot-blot, 
no protein expression was observed in the transgenic plants. Lack of protein 
expression might  result from several factors, including difference in codon usage 
between the animal virus and plant cells, post-transcriptional and post-translational 
processing between plants and animals, or rapid degradation of any protein product if 
produced. 
0) were generated. Histochemical and fluorometric GUS 
assays were carried out to check the expression in transformed  plants. Out of 9 
transgenic lines, two of the PCV promoter-GUS lines showed a slightly higher level, 
but not statistically significant, GUS activity in leaves compared to untransformed 
plants and one line showed a slightly higher level of GUS activity in root tissues 
compared to a CaMV35S-gus positive control  line. These results suggest that further 
study of this promoter, modifying its sequence more towards those present in plant v 
 
nanoviruses, might lead to higher levels  of expression of genes linked to this 
promoter. vi 
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1.1  General Introduction  
Jembrana disease virus (JDV) is a virus that infects Bos javanicus (Bali cattle) in 
Indonesia. It was characterised as a retrovirus on the basis of reverse trancriptase 
(RT) activity, virus morphology and C-type budding from cell membranes 
(Kertayadnya et al., 1993) and nucleotide sequence analysis confirmed that it was 
genetically similar to the bovine lentivirus,  Bovine immunodeficiency virus 
(BIV)(Chadwick et al., 1995b). The aim of this project was to introduce and express 
the genes SU (Surface unit glycoprotein) and fused CA-Tat (Capsid-Tat) into 
Nicotiana tabacum for production of recombinant antigens, which might be used as 
the basis of a vaccine in Bali cattle against JDV. 
An additional aim was to check whether an animal circovirus promoter fused to a 
reporter gene (GUS) and introduced into plants is expressed, so that it could be used 
as a novel plant promoter. 
The chapter focuses on the following broad areas: 
1.  JDV, its clinical signs and control measures 
2.  ‘Molecular pharming’ and progress in development of recombinant proteins 
in plants 
3.  Crop safety and issues relating to GM vaccines 
4.  Assessing the potential for an animal circovirus promoter for expression of a 
gene in plants 
 3 
 
1.2 JDV, its clinical signs and control measures 
1.2.1  Retroviridae  
Retroviruses are a group of viruses whose genetic material is comprised of RNA. In 
mammals, retroviruses are associated with a variety of diseases including 
malignancies, immunodeficiencies, and neurologic disorders (Rosenberg and 
Jolicoeur, 1997). Normally, the virions are 80 to 100 nm in diameter and their outer 
envelope is composed of glycoproteins. Each retrovirus particle contains two copies 
of 8-10 kb genomic RNA. An important feature of this family is its replicative 
strategy which includes as essential steps reverse transcription of the virion RNA into 
linear double-stranded DNA and the subsequent integration of this DNA into the 
genome of the host cell. Broadly, retroviruses are divided into two groups, simple and 
complex, distinguishable by the organization of their genome (Coffin, 1992, Murphy 
et al., 1994). Compared to a simple retrovirus genome containing only four major 
coding regions, gag, pro, pol, and env,  (Figure 1.1) a complex retroviral genome 
contains information for regulatory proteins besides the major coding regions (Vogt, 
1997). The family Retroviridae  is divided into seven genera: Alpharetrovirus, 
Epsilonretrovirus, Betaretrovirus, Deltaretrovirus, Gammaretrovirus, Spumavirus 
and Lentivirus to which JDV belongs.  
1.2.2  Lentiviruses  
Lentiviruses are generally associated with chronic diseases of  the immune system 
and the central nervous system (Aiken, 1998). These viruses are species-specific and 
members of this group infect a variety of hosts causing a unique disease syndrome in 
each host species. These can be categorised into five different groups accordingly: (i) 4 
 
Feline lentiviruses -  Feline Immunodeficiency Virus (FIV) and Puma Lentivirus 
(PLV); (ii) Primate lentiviruses - Human Immunodeficiency Virus (HIV-1 and HIV-2) 
and  Simian Immunodeficiency Virus  (SIV); (iii) Equine lentiviruses -  Equine 
Infectious Anaemia Virus  (EIAV); (iv) Bovine lentiviruses -  Bovine 
Immunodeficiency Virus (BIV) and Jembrana Disease  Virus  (JDV); (v) 
Ovine/caprine lentiviruses –  Maedi-Visna Virus  (MVV) and  Caprine Arthritis-
Encephalitis Virus (CAEV).  
Lentiviral genomes (Figure 1.1) contain the three major open reading frames (ORFs) 
common to all retroviruses; gag, pol and env. The gag genes direct the synthesis of 
internal virion proteins that form the matrix (MA), the capsid (CA) and the 
nucleocapsid (NC) protein structure. The pol region contains the information for the 
reverse transcriptase (RT) and integrase (IN) enzymes; and the transmembrane (TM) 
and surface (SU) components of the viral envelope proteins are encoded by the env 
coding region; and LTR (long terminal repeats). In addition to these, lentiviruses 
carry a variable number of accessory and regulatory proteins including Tat. 5 
 
 
Figure 1.1.  A lentiviral genome showing the relationship of various genes and 
location of different proteins.  Adapted from Gonda (1992). 
 
1.2.3  Jembrana Disease Virus 
1.2.3.1 History and distribution 
High mortalities were first reported in Bali cattle in the Jembrana district of Bali 
province, Indonesia, in December 1964 (Pranato and Pudijastoro, 1967). In the first 
outbreak, an estimated 60% of Bali cattle were affected with a mortality rate of 
98.9% (Ramachandran, 1996). Within 12 months, the disease spread rapidly to all 
eight districts of Bali with a mortality rate of about 20% (Wilcox et al., 1995). The 
disease was termed Jembrana Disease (JD). Due to strict regulation of the movement 
of Bali cattle from Bali to other islands in Indonesia, JD was confined to the island of 
Bali for more than 12 years. The first outbreaks of JD outside Bali were reported in 
Lampung, South Sumatra island in 1976 (Soeharsono and Darmadi 1976, 
Ramachandran 1981). Severe clinical and pathological changes with high morbidity 6 
 
and mortalitity rates similar to those in the first outbreak in Bali were reported. Illegal 
introduction of JD infected Bali cattle from Bali was the suspected cause of the 
outbreak. From Lampung, JD spread northwards to west Sumatra in 1992 (Tembok 
1992), Bengkalu in 1994 and South Sumatra in 1995. A recent genetic analysis of 
proviral-DNA samples obtained from cases of JD in Bali and Sumatra showed that 
JDV strains from the two islands were very similar, and displayed 97-100% amino 
acid homology (Desport et al., 2007). This supports the hypothesis that the most 
likely method of spread of JDV to Sumatra was  by  illegal transportation of 
persistently infected cattle from Bali (Hartaningsih et al., 1993, Soeharsono et al., 
1995). Therefore JD  is now regarded as endemic in Bali, Java, Sumatra and 
Kalimantan islands (Figure  1.2) of Indonesia, and is responsible for significant 
economic loses (Hartaningsih et al., 1993). 
 
Figure 1.2 Map of Indonesia. Areas where Jembrana Disease occurs in red. 
 
Wilcox et al. (1992) reported that the causative agent was a retrovirus and not a 
rickettsia as previously thought (Budiarso and Hardjosworo, 1976), as it could be 
filtered through a 100nm filter but was retained by a 50nm filter. The infectious agent 
present in the plasma was identified as a retrovirus on the basis  of electron 
microscopic studies demonstrating the presence of a spherical enveloped virus of 7 
 
about 100nm diameter with an eccentric core and by detection of reverse transcriptase 
(RT) activity in purified virus preparations (Kertayadnya et al., 1993, Wilcox et al., 
1992). The causative agent was characterised as a lentivirus, closely related to Bovine 
immunodeficiency virus (BIV), based on the antigenic cross-reactivity of the capsid 
protein (Chadwick et al., 1995b, Kertayadnya et al., 1993) and genomic sequence 
analysis and has  subsequently  been  named  as  Jembrana disease virus (JDV). 
Transmission of JDV has been reported to be similar to equine infectious anaemia 
virus (EIAV) and is likely to occur via hematophagous arthropods (tabanid flies) 
during the acute stage of the disease when the viral titre in blood is high (Soeharsono 
et al., 1995, Issel and Foil, 1984). 
1.2.3.2 Clinical signs 
The acute nature of JDV infection with high morbidity and mortality rates is unusual 
because most lentivirus infections generally cause a chronic and progressive disease 
after a long incubation period. After a short incubation period of 4-12 days, the major 
clinical signs which occur in infected cattle during the acute phase are characterised 
by fever persisting for 5-12 days, lethargy, anorexia, leukopenia, enlargement of 
superficial lymph nodes, a mild ocular and nasal discharge and diarrhoea with blood 
in the faeces (Soesanto et al., 1990). The most easily observed and striking clinical 
feature of JD is a significant enlargement of the superficial lymph nodes. This is a 
useful indicator in diagnosing JD under field conditions, together with enlargement of 
the spleen, which often is 3-4 times the normal size. This is a consistent pathological 
change in cattle with JD (Figure 1.3).  
                                 A                                                                    B 8 
 
 
 Figure 1.3 Consistent clinical and pathological changes of JD in Bali cattle: (A) marked 
enlargement of prescapular lymph node (B) enlargement of spleen which can be about 5 
times the size of a normal animal (Photo: ACIAR proceedings No. 75, 1996). 
JDV causes an acute disease atypical of most lentiviral infections and can lead to the 
death of the animal in 1 to 2 weeks (Wilcox et al., 1995, Wilcox et al., 1997). The 
typical progression of pathological changes after JDV infection can be divided into 
three distinguishable phases of disease (Dharma et al., 1991). Phase 1 consists of 
general lymphoreticular reaction which occurs during the first week post-infection 
(PI). Phase 2 lasts 8-21 days PI and is characterised by an intense non-follicular 
proliferation of dendritic and lymphoblastic cells, with infiltration of liver, kidneys, 
lungs and heart. This is followed by Phase 3 (4-5 weeks PI) which is characterised by 
marked lymphoid follicular reaction with plasma cell formation in the lymph nodes 
and spleen. These proliferative changes indicated that in  the  acute phase of the 
disease, a predominantly T-cell response occurs with a transient humoral 
immunosuppression  (Dharma  et al., 1991).  Animals  that  survive the primary 
infection develop immunity and become persistently viraemic although at low titre, 
for at least 24 months and possibly for life (Soeharsono et al., 1995). In addition, 
recovered animals are resistant against challenge with homologous or heterologous 9 
 
strains for at least 2 years after primary infection indicating the production of 
protective immunity (Soeharsono et al., 1990). 
1.2.3.3 Genomic organisation of JDV 
Sequence analysis of JDV demonstrated that it shares a similar organisation with 
other lentiviruses and  based upon nucleotide sequence homology, JDV is most 
closely related to the other bovine lentivirus, BIV (Chadwick et al., 1995a). The gag 
gene similarity between JDV genome and BIV127 was approximately 62% at the 
amino acid level and 21% in the env gene (Chadwick et al., 1995b). With a viral 
genome size of 7732bp, JDV is the lentivirus with the smallest genome identified 
thus far. The JDV genome (Figure  1.4) contains flanking long terminal repeats 
(LTRs) which contain transcriptional regulatory elements, and the 3 major open 
reading frames gag, pol and env.  
 
 
Figure 1.4 JDV complete genome showing the three ORFs. Regions in black represent 3 
major genes, while in red are regulatory and accessory genes which includes pol (derived 
from  polymerase) encoding viral enzymes, gag (derived from  group  antigen) encoding 
structural proteins), and env (derived from envelope) encoding envelope glycoprotein, vif 
encoding Vif (viral infectivity factor), tat encoding Tat (trans-activator of transcription), rev 
encoding Rev (regulator of expression of virus) and nef (ne
The Gag polyprotein is processed by viral proteases into three distinct domains: the 
matrix domain (MA), capsid domain (CA) and nucleocapsid domain (NC). The CA 
gative factor). 10 
 
protein is predicted to be 226 amino acids long (25.3kDa) and is immunodominant in 
infected animals. The Env polyprotein of JDV undergoes further cleavage by viral 
proteases to produce 359 amino acids long (41.1kDa) transmembrane (TM) and 422 
amino acids long (47.8 kDa) surface (SU) glycoproteins. In addition, JDV possesses a 
number of accessory and regulatory genes tat, rev, vif and tmx (Chadwick et al., 
1995b). Tat is potentially encoded for by two ORF’s, tat1 and tat2. JDV Tat1 is 97 
amino acids (10.7 kDa) and Tat 2 is 114 amino acids long (12.5 kDa). 
1.2.3.4 Vaccine against JDV 
Many vaccines against lentivirus infections have been developed and tested. Vaccines 
based on whole or inactivated virus preparations  have been most successful.  An 
inactivated tissue derived viral vaccine, ‘JDVacc’, has been developed containing 
detergent inactivated virus from  homogenised spleen taken from infected donor 
animals at the peak of viremia and is currently used to control  JD in Indonesia 
(Hartaningsih et al., 2001).  Two doses of JDVacc, which are given one month apart, 
are currently used as vaccination for Bali cattle in areas where JD outbreaks are still 
occurring. JDVacc has been shown to reduce the severity and duration of JD and it is 
likely that this amelioration of the acute phase of disease is sufficient to achieve a 
reduction in the mortality rates and  to  reduce the transmission of virus to other 
susceptible cattle (Hartaningsih et al., 2001, Ditcham et al., 2009). JDV strains in 
Bali appear to be highly genetically conserved (3% amino acid heterogeneity in env) 
and it is expected that JDVacc should offer good protection to cattle on this island 
(Desport et al., 2007). A JDV specific quantitative RT-PCR assay (qRT-PCR) has 
been developed and it has enabled the quantification of viral genomes in plasma 11 
 
samples taken during the course of infection and provided data that can be used to 
assess strain differences and vaccine efficacy (Stewart et al., 2005, Ditcham et al., 
2009, Desport et al., 2009). 
1.2.4  Capsid protein (CA) Vaccines 
There is broad conservation of antigenic epitopes of CA protein within the 
lentiviruses (Kertayadnya  et al., 1993). CA induces an early and strong antibody 
response when administered as a vaccine in animals infected with a lentivirus, 
including the bovine lentiviruses.  For plant generated vaccines, Agrobacterium-
mediated gene transfer was used to successfully introduce an HIV-1 p24 capsid 
protein gene into the genome of tobacco plants and to stably express in planta an 
antigenically-active form of the viral protein (Zhang et al., 2002). During the JD 
recovery phase, the earliest detectable immune response is against JDV capsid protein 
(Hartaningsh et al., 1994). Bali cattle vaccinated against JDV with the tissue-derived 
whole virus vaccine, and naturally recovered animals also develop strong antibody 
responses to CA (Ditcham et al., 2009, Lewis et al., 2009, Hartaningsh et al., 1994). 
This suggests that a CA based antigen is a good candidate for vaccine development. 
1.2.5  Transactivator (Tat) Vaccine 
There are also several reasons for targeting the Tat protein as an antigen for vaccine 
production. It is produced early during the virus life cycle and is essential for efficient 
virus replication  (Adams  et al., 1988, Arya  et al., 1985, Dayton  et al., 1986). 
Regulatory genes including JDV tat are genetically more conserved than structural 
genes such as  env. Tat is also antigenically conserved and highly immunogenic 
(Setiyaningsih et al., 2008). Candidate  lentiviral Tat antigens as potential vaccines  12 
 
have been produced in several forms, including as toxoid (Goldstein et al., 2001, 
Pauza et al., 2000), a peptide (Boykins et al., 2000, Goldstein et al., 2000), a protein 
either alone (Ensoli and Cafaro, 2000) or  in combination with modified Env (Ensoli 
et al., 2005) and a DNA vaccine (Allen et al., 2002, Cafaro et al., 2001, Caselli et al., 
1999, Hinkula et al., 1997). Vaccination experiments using inactive or active Tat 
protein in animal models were shown to induce specific immune responses and 
confer protection against disease progression (Agwale et al., 2002, Barillari et al., 
1999, Pauza et al., 2000). JDV Tat is a very potent transactivator of the long terminal 
repeats (LTR) and is able to transactivate the LTR of HIV and BIV with greater 
potency than the naturally encoded Tat proteins in experimental trials (Chen et al., 
2000, Chen et al., 1999). The most effective recombinant protein combinantion of 
JDV Tat+CA decreased the rate of appearance of viral genomes in the plasma in 
earlier stages of disease.  
1.2.6  Surface glycoprotein (SU) Vaccines 
The envelope glycoprotein of lentiviruses is encoded by the env ORF that produces a 
single chain precursor molecule. The precursor is cleaved by a host cell protease to 
produce two tightly associated structural glycoproteins, the surface unit (SU) and the 
transmembrane protein (TM). The SU is primarily an attachment molecule that 
influences virus tropism and recognition of specific host cell receptors (Gallaher et 
al., 1989). The SU plays a vital role in the first stage of the replication process and 
has the ability to induce a strong neutralising and non-neutralising antibody response, 
all these factors making it an ideal candidate for vaccine development (Ball et al., 
1992, Gallaher et al., 1995). Early studies indicated recombinant JDV SU prepared in 13 
 
bacterial expression systems did not provide any protective efficacy. The failure of 
JDV SU to induce a protective immune response was possibly associated with the 
lack of post-translational modifications of the protein in the bacterial system 
(Ditcham, 2007).  
1.3 ‘Molecular pharming’ in plants and progress in development of recombinant 
proteins 
Plants have been recognised as a promising production platform for recombinant 
pharmaceutical proteins over the past decade (Twyman et al., 2003). There has been a 
great deal of development in recombinant protein expression technologies in the past 
30 years with a variety of in vitro and in vivo systems emerging and each having 
weaknesses and strengths in their ability to express a range of foreign proteins (Mett 
et al., 2008).   
1.3.1  Recombinant proteins in transgenic plants 
The first transgenic plant was developed in 1983 (Fraley et al., 1983, Zambryski et 
al., 1983). Transgenic plants are potentially one of the most economic systems for the 
large-scale production of recombinant proteins for pharmaceutical and industrial uses 
(Austin et al., 1994, Krebbers et al., 1992, Pen et al., 1993). Recombinant protein 
production systems vary from prokaryotic systems such as Escherichia coli 
(Georgiou, 1988, Kudo, 1994); and Bacillus  (Udaka and Yamagata, 1993), to 
eukaryotic systems such as yeast (Harashima, 1994, Marino, 1991); mammalian cells 
(Warren and Krivi, 1991, Werner and Thomae, 1994), insect cell cultures (Goosen, 
1993, Luckow and Summers, 1988), transgenic animals  and a variety of plants. E. 
coli  is the workhorse of the biotechnology industry but it is not appropriate for 14 
 
expression of eukaryotic genes, particularly if the protein product must be 
glycosylated and processed post translation.  
The first pharmaceutically significant protein made in plants was human growth 
hormone, which was expressed in transgenic tobacco in 1986 (Barta et al., 1986). The 
idea of plant-based expression systems has since expanded to include industrial 
enzymes, blood components, cytokines, hormones, antibodies, and veterinary  and 
human vaccines (Goldstein and Thomas, 2004).  Eleven plant-derived non-
pharmaceuticals proteins (avidin, trypsin, β-glucuronidase, aprotinin, lactoferrin, 
lysozyme, thyroid-stimulating hormone receptor, Hantaan and Puumala viral 
antigens, peroxidase, laccase and cellulase) have been developed and marketed 
(Basaran and Rodriguez-Cerezo, 2008).  There are no  plant-made pharmaceutical 
products currently on the market, but so far eighteen plant-derived pharmaceuticals 
have been submitted for phase I and II clinical trials (Table 1.1). 15 
 
Table 1.1 Plant derived pharmaceutical proteins that are closest to commercialisation 
for the treatment of human and animal diseases  (Basaran and Rodriguez-Cerezo, 
2008) 
Product  Treatment  Company  Recombinant 
source  Status 
CaroRx  Dental caries 
Planet 
Biotechnology Inc. 
(USA) 
Nicotiana 
tabacum 
(Tobacco) 
Phase II 
Rhino RX 
Respiratory 
syncytical 
disease 
Planet 
Biotechnology Inc. 
(USA) 
Nicotiana 
tabacum  Phase I 
Antibody  Cancer  NeoRX/Monsanto 
(USA)  Zea mays (Corn)  Phase II 
IgG (ICAM1)  Common cold 
Planet 
Biotechnology Inc. 
(USA) 
Nicotiana 
tabacum  Phase I 
E.coli heat labile 
toxin  Diarrhoea 
ProdiGene (USA) 
 
Arizona State 
University (USA) 
 
Zea mays 
 
Solanum 
tuberosum 
(Potato) 
Phase I 
 
Phase I 
Vibrio cholerae  Cholera  Arizona State 
University (USA) 
Solanum 
tuberosum  Phase I 
HBsAg  Hepatitis B 
Thomas Jefferson 
University (USA) 
Arizona State 
University (USA) 
 
Lactuca sativa  
(Lettuce) 
 
Solanum 
tuberosum 
Phase I 
 
Phase II 
Lt-B vaccine  Traveller’s 
diarrhoea  ProdiGene (USA)*  Zea mays  Phase I 
TGE vaccine  Piglet 
gastroenteritis  ProdiGene (USA) *  Zea mays  Phase I 
Norwalk virus capsid 
protein 
 
Diarrhoea 
 
Arizona State 
University (USA) 
Solanum 
tuberosum 
Solanum 
lycopersicum 
(Tomato) 
 
 
Phase I 
 
Newcastle vaccine 
Newcastle 
disease virus 
infection, poultry 
Dow Agro (USA)  Cultured 
transgenic cells 
Approved 
(USDA) 
commercial 
Viral vaccine mixture 
Diseases of 
horses, dogs, and 
birds 
Dow Agro (USA)  Tobacco 
transgenic cells 
Phase I 
 
Cancer vaccine  Non-Hodgkin’s 
lymphoma 
Large Scale Biotech 
(USA) 
Nicotiana 
tabacum  Phase II 
Viral vaccine  Feline parovirus  Large Scale Biotech 
(USA) 
Nicotiana 
tabacum  Phase II 
Poultry vaccine  Coccidiosis 
infection 
Guardian 
Biosciences 
(Canada) 
Brassica napus 
(Canola)  Phase II 
Gastric lipase  Cystic fibrosis  Meristem 
Therapeutics (EU) 
Zea mays 
Nicotiana 
tabacum 
Phase II 16 
 
Product  Treatment  Company  Recombinant 
source  Status 
Hepatitis B virus 
surface antigen  Hepatitis B 
Arizona State 
University (USA) 
 
Thomas Jefferson 
University/ Polish 
Academy of 
Sciences 
Solanum 
tuberosum 
 
 
Lactuca sativa 
Phase I 
 
 
 
Phase I 
Human intrinsic 
factor 
Vitamin B12 
deficiency 
Cobento Biotech 
AS (EU) 
Arabidopsis 
thaliana  Phase II 
Lactoferrin  Gastrointestinal 
infections 
Meristem 
Therapeutics (EU) 
Ventria Biosciences 
(USA) 
Zea mays 
 
Oryza sativa  
(Rice) 
Phase I 
 
Phase I 
α-Galactosidase  Fabry disease  Planet Biotech 
(USA) 
Nicotiana 
tabacum  Phase I 
α-interferon  Hepatitis B&C  Biolex (USA)  Lemna 
(Duckweed)  Phase II 
Interleukin  Crohn’s disease 
Southern Crop 
Protection and Food 
Research Centre 
(Canada) 
Nicotiana 
tabacum  Field trials 
Fibrinolytic drug 
(thrombolytic drug) 
Blood clot 
dissolver 
Biolex (USA) 
  Lemna  Phase I 
Glucocerebrosidase  Gaucher’s 
disease  Protalix (Israel)  Daucus carota  
(Carrot) Cells  Phase III 
Insulin  Diabetes  Sembiosys (Canada) 
Carthamus 
tinctorius 
(Safflower) 
Phase I 
Apolipoprotein AI  Cardiovascular  Sembiosys (Canada)  Carthamus 
tinctorius  Phase I 
Rabies glycoprotein  Rabies  (Yusibov et al., 
2002) 
AMV and TMV  
in Spinacia 
oleracea 
(spinach) 
Phase I 
* See section 1.4 for more information on Prodigene  
AMV - Alfalfa mosaic virus; TMV - Tobacco mosaic virus 
 
1.3.2  Viral vectors for production of vaccines 
Plant viral vectors are an alternative approach for production of pharmaceuticals in 
plants (Pogue et al., 2002). Plant viruses are not transmitted to humans or animals 17 
 
and can accumulate very large amount of heterologous proteins in host plants. Two 
major approaches are ‘full virus’, which uses expression of large fusion proteins with 
the coat protein and another is a ‘deconstructed virus’, which relies on Agrobacterium 
as a vector to deliver DNA of one or more viral RNA replicons to plant cells. The 
plant virus approach is limited primarily by the number and type of genes for proteins 
that can be introduced and expressed into the virus genome, whilst allowing it to 
replicate in host plant cells (Gleba et al., 2007). 
1.3.3   Recombinant antibodies produced in plants 
Since the expression and assembly of  secretory  immunoglobulin (Ig) A was first 
shown in transgenic tobacco plants in 1998 (Ma et al., 1995, Ma et al., 1998), plants 
have proved to be versatile production systems for many forms of antibodies. Most 
antibodies expressed so far have been in tobacco, although recently alfalfa, rice, 
potatoes, soybean duckweed, safflower, canola, maize and wheat have also been used 
effectively (Artsaenko et al., 1998, Zeitlin et al., 1998, Khoudi et al., 1999, Stoger et 
al., 2000, Torres et al., 1999). Many recombinant antibodies have been expressed 
widely in plants as modulators  of plant  cell processes (Owen  et al., 1992),  for 
phytoremediation purposes (Longstaff et al., 1998, Drake et al., 2002), to confer virus 
resistance  (Villani  et al., 2005),  and for the biosynthesis of valuable 
immunotherapeutic agents (Ko and Koprowski, 2005, Ma et al., 2003, Brodzik et al., 
2006, Ramessar  et al., 2008, Hull  et al., 2005). Single chain antibody (scFv) 
expressed in seeds of rice and wheat showed high biological activities and remained 
stable for several years (Stoger et al., 2005). Recently, an anti-hepatitis B surface-18 
 
antigen  antibody received regulatory approval in Cuba for large-scale plant-made 
antibody production (Pujol et al., 2005).  
1.3.4  Vaccines produced in plants 
Expression of antigenic proteins of viral and microbial pathogens were some of the 
earliest examples chosen to study the viability of transgenic plant expression systems 
(Haq et al., 1995, Mason et al., 1996, Mason et al., 1992, McGarvey et al., 1995). 
The first demonstration of expression of a vaccine antigen in plants was in 1990, 
when  Streptococcus mutans  surface protein antigen A  (SpaA) was expressed in 
tobacco (Curtiss and Cardineau, 1990).  Early work with plant-based subunit vaccines 
used readily transformed species like tobacco, potato and tomato (Haq et al., 1995, 
Mason et al., 1996, Mason et al., 1992, McGarvey et al., 1995, Arakawa et al., 1997). 
However, the most attractive species for expressing subunit vaccine components 
should produce high levels of soluble protein that is stable during storage; seed crops 
such as cereals or oilseed crops are particularly suitable. The quantity of plant tissue 
expressing a vaccine dose must be of a practical size for consumption. Thus, 
achieving a high level of expression is crucial. The expression of vaccine components 
in plants has been increased by using a range of polyadenylation and leader signals 
(Richter et al., 2000) and by optimising codon usage for plants (Tuboly et al., 2000, 
Streatfield  et al., 2000, Mason  et al., 1998). Expression could also be increased 
through crosses of transformed lines to various genetic backgrounds, an approach that 
has been successfully applied to raise protein production in corn. The stability of 
heterologous proteins and the assembly of multi-subunit structures depends on the 
cellular environment and therefore on the subcellular location. Preferred locations for 19 
 
the expression of selected subunit vaccine components are the cell surface, golgi body 
and the endoplasmic reticulum (Haq et al., 1995, Arakawa et al., 1997, Tuboly et al., 
2000, Tackaberry et al., 1999, Richter et al., 2000).  
There are two routes commonly used to generate antibodies to antigens in mammals -
either delivery by injection or by direct delivery to mucosal surfaces. Plant-expressed 
antigens have been shown to be capable of inducing mucosal and serum immune 
responses when administered orally or parenterally to experimental animals 
(Berinstein et al., 2005, Ashraf et al., 2005, Kohl et al., 2006, Hahn et al., 2007). A 
few of these vaccine candidates have been successfully tested in clinical trials or in 
commercial or native animal trials (Kapusta  et al., 1999, Castanon  et al., 1999, 
Streatfield et al., 2000, Tuboly et al., 2000, Mason et al., 1998, Tacket et al., 2000, 
Tacket et al., 1998). To date, the results of at least eleven clinical trials have been 
published and several candidate vaccines are ready to be approved for phase II trials 
(Yusibov and Rabindran, 2008, Basaran and Rodriguez-Cerezo, 2008).  
1.3.5  Plant-based vaccines for animals  
A number of viral and bacterial antigens produced in plants have already 
demonstrated their immunogenicity when orally administrated (Mason et al., 1996, 
Haq et al., 1995, Arakawa et al., 1998, Wigdorovitz et al., 1999, Gomez et al., 2000, 
Yu and Langridge, 2001). Plant-based vaccines are subunit vaccines, so there are 
likely to be fewer safety concerns as compared to live delivery vehicles. The rate at 
which new candidates are being expressed in plants or previously selected candidates 
expressed in alternative plant systems has lead to a rapidly growing number of 
antigen expression studies in plants (Streatfield, 2005). In a feeding trial targeting 20 
 
transmissible  gastroenteritis virus in swine, an initial injection regime  was 
administered to sows, and then a corn-based  vaccine was delivered orally. This 
resulted in improved levels of neutralising antibodies in the ‘sows’ serum and, more 
significantly, in their colostrum and early milk (Lamphear et al., 2004). Since piglets 
are most susceptible to infection soon after birth, when they are dependent on the 
sow’s milk, high neutralising antibody levels in the colostrum may be the best way to 
provide protective immunity. 
A further study demonstrating lactogenic immunity has been done in mice, where 
dams were immunized orally by  a potato tuber-based rotavirus vaccine. Suckling 
pups were protected against challenge with the virus, indicating that they had 
acquired passive immunity (Yu and Langridge, 2001). In a similar study, an epitope 
of a bovine rotavirus protein expressed in alfalfa was delivered orally to dams and the 
suckling pups were protected against challenge with the virus (Wigdorovitz et al., 
2004).  Swine transmissible  gastroenteritis virus vaccine, the most advanced plant 
based vaccine candidate for animal health on which data has been published, has 
shown great potential for further development. In this case, the selected antigen was 
expressed at a sufficiently high level to allow for oral delivery, and efficacy data 
appears to be very promising  (Lamphear  et al., 2004, Streatfield  et al., 2001, 
Lamphear et al., 2002, Judge et al., 2004). There are several instances in which the 
delivery of an edible plant-based vaccine to animals can also serve to protect human 
health. Rabies (Modelska et al., 1998) and E. coli O157:H7 (Judge et al., 2004) are 
examples of two target diseases for which plant based vaccines are in the early stages 
of development and the use of these vaccines would impart protection to both animals 
and humans. Recombinant HIV-1/HBV virus-like particles (VLPs) were successfully 21 
 
expressed in Nicotiana tabacum and Arabidopsis thaliana (Greco et al., 2007). HIV-1 
Tat protein expressed in spinach plants was explored as a potential vaccine candidate 
in mice (Karasev et al., 2005). 
1.3.6   Post translational processing 
The protein-synthesis pathway is highly conserved between plants and animals, so 
animal transgenes which are expressed in plants yield proteins with identical amino 
acid sequences to their native counterparts. One of the advantages of the plant 
production systems is the ability to perform post-translational modifications such as 
protein glycosylation (Kusnadi  et al., 1997). In plants Asn-X-Ser or Asn-X-Thr 
tripeptides can function as glycan acceptors just as in mammalian polypeptides. As in 
mammalian cells, the glycan processing machinery of plant cells is located in the 
endoplasmic reticulum (high mannose) and the golgi apparatus (complex type; 
additional fucose and xylose residues). Molecules can be targeted to endoplasmic 
reticulum to avoid complex-type glycosylation (Mett et al., 2008). Recombinant α-
amylase produced in tobacco was glycosylated in contrast to the wild-type α-amylase 
from barley (Pen  et  al., 1993, Pen  et al., 1992). Differential glycosylation of 
recombinant β-phaseolin was also observed in tobacco (Hoffman et al., 1988). An 
inducible tobacco expression system has been used to produce active glycosylated 
human glucocerebrosidase, a lysosomal enzyme (Cramer et al., 1996). Properties of 
the recombinant protein such as biological activity, protein folding, stability, and 
solubility could be affected by glycosylation (Marino, 1991). For pharmaceutical 
purposes, recombinant proteins have to be identical to the wild type protein even 
though different forms may have exactly the same characteristics as the wild-type 22 
 
(Kusnadi et al., 1997). Several studies involving recombinant proteins produced in 
plants have shown that the proteins can undergo self-assembly. A complex secretory 
immunoglobulin consisting of four polypeptide chains assembled into a functional 
antibody in tobacco plants that expressed all four polypeptide simultaneously (Ma 
and Hein, 1995).  
1.3.7  Plant expression hosts 
The choice of plant to be used for expression of recombinant proteins depends on a 
number of factors that include its cultivation method, transformability, growing cost, 
ability to segregate from the normal human food chain, production and processing of 
the target tissue, existence of wild relatives, and degree of outcross with wild relatives 
(Howard and Hood, 2005).  The major advantage of using green tissue (tobacco, 
alfalfa, and soybean) is total productivity, but soybean is a major human food which 
is a significant disadvantage. 
1.3.7.1  Tobacco as a production system 
Tobacco is the most widely used species for the commercial production of 
recombinant proteins (Basaran and Rodriguez-Cerezo, 2008). The major advantages 
of tobacco include the high biomass yield, the established technology for gene 
transfer and expression, the potential for rapid scale up, and the existence of large 
scale  processing infrastructure. Under field conditions, tobacco can produce over 
50,000kg/ha of fresh biomass in a single season (Woodlief et al., 1981). It is a non-
food, non-feed crop that carries a reduced risk of transgenic material contaminating 
feed and human food chains (Stoger  et al., 2005). Successful commercial use of 23 
 
tobacco as a transgene expression system includes INPACT (In-Plant Activation 
Technology) developed by Farmacule Bioindustries (www.farmacule.com). 
1.3.7.2  Cereals and legumes 
Maize was the main commercial production crop for recombinant proteins. It offers 
several  advantages such as high biomass yield, ease of transformation and in vitro 
manipulation, and ease of scale-up (Ma et al., 2003). Maize has been used for the 
production of avidin and β-glucuronidase (Hood et al., 1997, Witcher et al., 1998); 
recombinant antibodies (Hood et al., 2002) and the pharmaceutical enzymes- laccase, 
trypsin and aprotinin (Hood, 2002).  
Grain legumes are useful production crops because of the high protein content in 
seeds. Alfalfa and soybean have been used to produce recombinant antibodies (Zeitlin 
et al., 1998, Khoudi et al., 1999). Both of these plants have the major advantage of 
using atmospheric nitrogen through nitrogen fixation, therefore reducing the need for 
chemical fertilisers (Ma et al., 2003).  
1.3.7.3  Fruit and vegetables crops 
The main benefit of fruit, vegetable and leafy salad crops is that, at least in theory 
they can be consumed raw or partially processed, which makes them particularly 
suitable for the production of recombinant subunit vaccines, food additives and 
antibodies for topical passive immunotherapy. Potatoes, although not normally eaten 
raw,  have been used for the production of plant-derived vaccines and have been 
administered to humans in most of the clinical trials carried out so far. Potato has 
been used for the production of antibody-fusion proteins (Schunmann et al., 2002), 24 
 
single-chain Fv (scFv) antibodies (Artsaenko  et al., 1998), human milk proteins 
(Chong and Langridge, 2000, Chong et al., 1997), cholera toxin B-subunit-anthrax 
LF conjugate fusion protein (Kim et al., 2004). Tomatoes were used to produce the 
first plant-derived rabies vaccine (McGarvey  et al., 1995), F1-V antigen fusion 
protein of Yersinia pestis, the causative agent of plague (Alvarez et al., 2006) and are 
more palatable than raw potatoes. Transgenic tomatoes and transgenic potato tubers 
carrying a gene for Norwalk virus capsid protein have undergone clinical trials where 
tomato-delivered proteins were found to be more effective than potato-derived ones, 
probably because of different digestibility and absorbance in the gastrointestinal tract 
of humans (Tacket et al., 2000). Lettuce is also being investigated as a production 
host for edible recombinant vaccines, and has been used in one series of clinical trials 
for a vaccine against hepatitis B virus (Kapusta et al., 1999). Transgenic lettuce has 
also been successfully used to express Measles virus hemagglutinin protein and found 
to be immunogenic in mice (Webster et al., 2006). Bananas (Kumar et al., 2005), 
cherry tomatillos (Gao et al., 2003) and carrots (Bouche et al., 2003) have also been 
used to produce vaccine antigens. 
1.4 Crop safety and issues relating to GM vaccines 
Plant vaccines offer many potential advantages, but there also exists the potential for 
unintended consequences. There are a number of social, ethical and environmental 
issues for such genetically modified products  (Jan-Peter  et al., 2003).  The most 
frequently cited are environmental biosafety issues, such as potential for transgene 
spread and the possible toxicity of the recombinant proteins to nontarget organisms. 
These    need to be addressed on a case-by-case basis depending on the location, 25 
 
production host and product, taking into account measures that have been used to 
reduce biosafety risks (Commandeur et al., 2003).  
Use of food and feed crops as production hosts is of greater concern for plant derived 
pharmaceuticals.  It is essential to make sure that both in the field and post-harvest, 
which includes transport and processing, adequate isolation measures are in place. 
Unlike conventional crops, plant made pharmaceuticals (PMPs) are currently grown 
in secure environments. Crops that can cross pollinate with related wild species are 
eliminated. Planting non transgenic border rows around the pharmaceutical crop can 
enhance containment of pollen and is generally a legislative requirement. PMPs 
expressed in leaves can be harvested before flowering and this will prevent release of 
pollen in the environment. In some cases, male sterile lines can be used for the 
containment of transgenic crops. In Australia, under the Gene Technology Act 2000 
(http://www.ogtr.gov.au/pubform/legislation.htm
So far, only small-scale feeding studies have been conducted with plant-based 
vaccines; thus, there is limited data on safety. However, the studies completed so far 
have not raised any safety concerns. Most notably, no safety concerns have been 
), all intentional environmental 
releases of GMOs, i.e. both field trials and commercial releases, must be licensed. 
The USDA (US Department of Agriculture) has a zero tolerance policy. In 2002, 
Prodigene was fined $250,000 and ordered to pay more $3million by the USDA in 
penalties for mixing genetically engineered corn containing an animal vaccine with 
soybeans meant for humans. This resulted in the closure of Prodigene as a company. 
Clearly it is vital to ensure that separate pathways are retained for food/feed and 
plants for pharmaceuticals production. 26 
 
identified following the testing of several plant-based vaccines in human phase I 
clinical trials (Tacket et al., 2000, Kapusta et al., 1999, Tacket et al., 1998, Tacket et 
al., 2004, Yusibov et al., 2002). Furthermore, since they are recombinant subunit 
vaccines and are produced in expression systems that are not known to harbour 
human or target-animal pathogens, plant-based vaccines should be free of disease 
causing agents.The regulatory process is  greatly simplified for animal vaccines 
compared to human vaccines.  
Another particular concern is the potential to induce tolerance, as repeated exposure 
to an oral antigen has the potential to produce immunological tolerance or 
unresponsiveness. However, it was reported that the antigen doses necessary to 
induce protection are  generally smaller than that required to produce tolerance 
(Tripurani et al., 2003). 
1.5 Porcine circovirus (PCV) promoter for expression of reporter gene in plants 
There are a limited number of constitutive promoters available to drive gene 
expression in plants. Most (eg CaMV35S) are derived from plant DNA viruses. The 
plant nanoviruses are closely related to animal circoviruses, therefore the possibility 
existed that an animal circovirus promoter could also act as a plant promoter. This 
would provide novel intellectual property (IP) and freedom to use such a promoter to 
drive gene expression of a JDV gene based antigen in plants. 
1.5.1   Porcine circovirus 
Porcine circovirus (PCV) belongs to family Circoviridae and is the smallest animal 
virus known to replicate autonomously. Its genome consists of 1759 nt long circular, 27 
 
single-stranded and covalently closed DNA molecule (Tischer et al., 1982). The PCV 
genome encodes two open reading frames (ORFs). The largest ORF encodes two 
replication proteins, Rep and Rep´. Both of these proteins are essential for viral 
replication. The second largest ORF encodes the capsid protein Cap. PCV can be 
related to plant circoviruses and geminiviruses based on the alignment of origin of 
replication and of the Rep protein (Mankertz et al., 1997) and it may represent a link 
between plant and animal circoviruses (Meehan et al., 1997).  
1.5.2  PCV rep gene Promoter 
The rep gene promoter (Prep) is 156bp in length (Figure 1.5) which is located at  
position 640-796. It overlaps with the intergenic region and the origin of replication. 
It contains several regions which include an SP1 site located at position 693-698nt 
and downstream to the SP1 site is the TATA box (739-745). The TATA box overlaps 
a IFN-stimulatory response element (ISRE) which resides at position (740-753). An 
AP3 box (nt 642-653) and an AP4 box (nt 760-768)  are  also found in the Prep 
(Mankertz and Hillenbrand, 2002).  It also contains a putative stem loop sequence 
with a nanomer  at  its top. Two repeats of the hexamer 5´CGGCAG are located 
adjacent to the stem-loop sequence. 28 
 
 
Figure 1.5 Linear map of the genome of PCV showing promoter Prep and Pcap 
1.5.3  Circoviruses vs nanoviruses 
(Mankertz and 
Hillenbrand, 2002). 
 
Circoviruses and nanoviruses have similar circular single-stranded genomes (Meehan 
et al., 1997).  Nanoviruses, such as Coconut foliar decay virus  (CFDV),  Banana 
bunchy top virus  (BBTV) and Subterranean clover stunt virus  (SCSV) were 
previously classified as Circoviridae, but they are now classified as Nanoviridae. 
Although they are no longer in the same family, the plant and animal circoviruses 
have conserved regions in their genomes associated with conserved functions such as 
replication (Bassami et al., 1998). The sequence of the ORF encoding the replication-
associated (Rep) protein is highly conserved between PCV, Beak and feather disease 
virus  (BFDV),  Goose circovirus  (GCV),  Pigeon (columbid) circovirus  (CoCV), 
Canary circovirus (CaCV), nanoviruses and some geminiviruses (Todd et al., 2001, 29 
 
Bassami et al., 1998, Phenix et al., 2001). The Rep protein of viruses in the genus 
circovirus, the plant nanoviruses and the geminiviruses all contain common dNTP-
binding motifs, characteristic of proteins involved in rolling circle replication 
(Mankertz et al., 1998b, Niagro et al., 1998). A nt-binding site, often referred to as a 
P-loop motif, is also conserved between the Rep proteins of these viruses (Niagro et 
al., 1998, Mankertz et al., 1997). There is little variation in these motifs between 
PCV, BFDV, CFDV, BBTV and SCSV, and their rep proteins exhibit a high degree 
of amino acid similarity (Mankertz et al., 1997). The presence of a nonanucleotide 
sequence at the top of a  potential stem-loop structure,  identical to that found in 
nanovirus CFDV and homologous to that found in the geminivirus nonanucleotide 
motif suggests that rolling circle replication (RCR) may operate during circovirus 
DNA replication. 
 
Table 1.2 Stem loop sequence of the animal circoviruses  and some nanoviruses 
(Todd et al., 2001, Boevink et al., 1995, Rohde et al., 1990) 
 
Virus  9 nt sequence  Stem-loop  Stem-loop size 
PCV  TAGTATTAC  Yes  12 
SCSV  TAGTATTAC  Yes  11 
BBTV  TA(G/T)TATTAC  Yes  11 
CFDV  TAGTATTAC  Yes  10 
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1.5.4  Plant transformation promoters  
One of the most important aspects of construct design for molecular farming is the 
promoter used to drive transgene expression. The most widely used promoter is the 
35S promoter of Cauliflower mosaic virus (CaMV35S) (Covey et al., 1981), which is 
a part of transgenic constructs in more than 80% of genetically modified plants (Hull 
et al., 2000). This promoter constitutively drives the expression of the transgene due 
to its high transcription activity.  
Table 1.3 Examples of various promoters which have been used for recombinant 
protein expression in plants 
Plant  Promoter  Disease  Antigenic 
protein  Reference 
Potato  Mannopine 
synthase  Cholera  CTB  (Arakawa et al., 
1997) 
Tomato  Fruit specific E8  Cholera  CTB  (Jiang et al., 2007) 
Potato  Tuber-specific 
patatin 
Diarrhoea  LTB  (Lauterslager et al., 
2001) 
Tobacco  Plastid 16S rRNA 
gene promoter  Diarrhoea  LTB-Heat stable 
toxin (ST) 
(Rosales-Mendoza 
et al., 2009) 
Banana 
Ubq3 and 
ethylene forming 
enzyme (EFE) 
Hepatitis  HBsAg  (Kumar et al., 2005) 
Tomato  Fruit specific 
2A11  Hepatitis  PRS-S1S2S  (Lou et al., 2007) 
Potato 
CaMV35S, 
sunflower 
polyubiquitin and 
B33 patatin 
Rabbit 
hemorrhagic 
syndrome 
Structural protein 
VP60 
(Castanon et al., 
2002) 
Tobacco  Plastid rRNA 
operon (Prrn)  Cholera  CTB 
(Daniell et al., 
2001) 
 
Tobacco  psbA 
Cholera and 
haemorrhagic 
gastroenteritis 
and mycocarditis 
CTB-2L21  (Molina et al., 
2004) 
Rice  Wheat endosperm 
specific Bx17  Cholera  CTB  (Oszvald et al., 
2008) 
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However, its efficiency is dependent on the plant species. Various seed specific 
promoters such as legA from pea, dlec2 from bean (Perrin et al., 2000), lectin from 
soybean (Philip et al., 2001), Gb-1 and Gt-1from rice (Yang et al., 2003) have been 
used to restrict recombinant protein expression to different parts of the seed. Various 
other promoters have also been used for stable expression of vaccine antigens in 
plants (Table1.3). 
 
1.5.5   Gus as a reporter gene 
The bacterial enzyme β-glucuronidase is encoded by the E. coli uidA (gusA) gene and 
utilizes the external substrates 4-methyl umbelliferyl glucuronide (MUG) which is 
converted into the fluorescent 4MU molecule for sensitive quantification and 5-
bromo-4-chloro-3-indolyl glucuronide (X-gluc) for histological localization 
(Jefferson, 1989). The β-glucuronidase (GUS) gene is widely used as a reporter gene 
in transgenic plants because gene expression can be quantified by fluorometric and 
spectrophotometric analysis (Gartland et al., 2000). It is very straightforward and 
requires no expensive equipment. GUS reporter gene fusion systems have been used 
for various purposes including studying developmental patterns of gene expression; 
for standardisation of  the particle bombardment parameters; to compare different 
transformation methods; to compare the best tissue culture media for selection and 
regeneration and for promoter analysis (to identify promoter sizes and motifs useful 
for controlling gene expression in transgenic plants).  
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1.6 Project aims 
Plants potentially offer a safe, alternative system for the production of antigens, and 
large scale and low cost production of antigens is possible. In addition, plants provide 
improved post-translational modifications compared to bacterial systems. Plant 
production of antigens reduces the need for sophisticated culture/production facilities.  
The overall aim of this project was to transform viral genes (fused CA-Tat and SU 
encoding region) of the JDV genome into tobacco plants. Specific aims were: 
1.  To undertake the required cloning to make constructs for JDV genes 
2.  To generate transgenic plants containing these genes 
3.  To study the level of expression of the antigenic proteins 
4.  If time, to test their antigenic effects 
A subsidiary aim was to find out whether porcine circovirus promoter could drive 
gene expression in plants. 
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Chapter 2 
General Materials and Methods 
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2.1 General materials 
2.1.1 Specialised reagents 
All general laboratory reagents were purchased from scientific supply companies 
including Sigma (NSW, Australia) or BioRad (NSW, Australia). Agarose used for gel 
electrophoresis was supplied by Fisher Biotec (Perth, Australia). All DNA markers, 
modifying and restriction enzymes were purchased from Promega (NSW, Australia), 
Fermentas (USA) or New England Biolabs (USA). 
2.1.2 Bacterial strains used 
Escherichia coli strain JM109 were used for all plasmid cloning and Agrobacterium 
tumefaciens strain AGL0 was used for leaf disc transformation of tobacco. 
2.1.3 Deoxyribonucleotides synthesis 
Oligonucleotides were synthesised by Geneworks (South Australia) and supplied at a 
concentration of 100µM. Primers were diluted to 20µM working concentration prior 
to PCR. 
2.1.4 General solutions  
Most of the solutions were prepared according to (Sambrook et al., 1989). 
Agarose gel loading dye (6X): 0.25% bromophenol blue, 50% glycerol, 50% TE 
CTAB buffer: 100mM Tris-HCL, 1.4mM NaCl and 20mM EDTA 
IPTG: Isopropyl-β-D-galactopyranoside, prepared as 0.1M in sterile dH20 
Luria-Bertani (LB) liquid growth media:  Bacto-tryptone  1%  (w/v), bacto-yeast 
Extract 0.5% (w/v), NaCl 0.5% (w/v) 
Luria-Bertani (LB) agar: LB liquid growth media with 1% bacteriological Agar 35 
 
Phosphate buffer saline  (PBS):  8g NaCl, 0.2g KCl, 1.44g Na2HPO4, 0.27g 
KH2PO4, pH 7.4, makeup the volume 1L with dH2O 
PBS-T: PBS with 0.05% Tween 20 
SOB medium: 2% bacto-tryptone, 0.5% bacto-yeast extract, 10mM Nacl, 2.5mM 
KCl, 10mM MgCl2, 10mM MgSO4 
SOC medium: 2% bacto-tryptone, 0.5% bacto-yeast extract, 10mM Nacl, 2.5mM 
KCl, 10mM MgCl2, 10mM MgSO4, 20mM glucose 
TE buffer: 10mM Tris-HCl, pH 8.0, 1mM EDTA 
TB buffer: 10mM HEPES, 15mM CaCl2, 55mM MnCl2
MS+B5 (Sigma) 
, 25mM KCl 
TAE Buffer (1X): 10mM Tris.acetate, 0.5mM EDTA pH 7.8 
X-gal:  5-bromo-4-chloro-3-indoly-β-D-galactopyranoside, 50mg/ml prepared in 
dimethyl formamide (DMF) 
CM1 Solid medium (1L): 
4.4g 
Sucrose  30g 
pH  5.7 
Agar  8g 
BAP (1mg/ml)  1000µl 
NAA (1mg/ml)  100µl 
(CM1 liquid medium without agar) 
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SM1 medium (1L):  
MS+B5  4.4g   
Sucrose  30g   
pH  5.7   
Agar  8g   
BAP (1mg/ml)  1000µl   
NAA(1mg/ml)  100µl   
Timentin (200mg/ml)  1000µl   
Hygromycin (50mg/ml)  1000µl  P1303* 
Glufosinate (20mg/ml)  500µl  JFH2* 
* Plant transformation vectors 
SM2 medium (1L): 
MS+B5  4.4g   
Sucrose  30g   
pH  5.7   
Agar  8g   
Timentin(200mg/ml)  1000µl   
Hygromycin(50mg/ml)  1000µl  P1303 
Glufosinate(20mg/ml)  500µl  JFH2 
 
RM medium 1L: 
MS+B5  4.4g 
Sucrose  30g 
pH  5.7 
Agar  8g 37 
 
2.2 General Methods 
2.2.1 DNA amplification, cloning and sequencing 
2.2.1.1 General PCR procedure 
All PCRs consisted of 200µM dNTPs, 1x PCR buffer, 1.5-2.0mM MgCl2
2.2.1.2 Restriction enzyme digestion 
, 20pmol of 
each primer, 1-2.5U of Taq DNA polymerase and reaction volumes ranged from 20-
50µl. A typical PCR profile was: initial denaturation step of 94ºC for 3min, followed 
by 25-35 cycles of denaturation at 94ºC for 30sec, primer annealing at 55ºC for 30sec 
and extension at 72ºC for 1min, then a final incubation step at 72ºC for 10min to 
ensure complete extension.  
Plasmid DNA (upto 1µg) was incubated with appropriate restriction enzyme (1-10U) 
at 37°C for 1-16h, in the presence of 1x restriction buffer. Generally reactions were 
carried out in a volume of 20µl. 
2.2.1.3 Alkaline dephosphorylation of plasmid vectors 
The 5’phosphate groups of the linearised vector were removed using calf intestinal 
alkaline phosphatase (CIAP, Fermentas). The linearised vector after digestion was 
either purified from agarose gel or from solution and treated with 0.5U of CIAP/µg of 
DNA. The reaction mixture was mixed thoroughly and incubated at 37°C for 30min. 
The reaction was stopped by heating at 75°C for 5min. 
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2.2.1.4 DNA ligation 
Appropriate amounts of PCR products and vector were mixed in a molar ratio 
according to the following equation: 
ng of vector x kb of insert x insert : vector molar ratio = ng of insert 
kb size of vector  
 
The PCR product (varied) was mixed with  10x  Ligation  Buffer  (1μL),  pGEM-T 
Vector 50ng/μL (1μL), T4 DNA Ligase (1μL), and the reaction was made up to 10μL 
with dH
2
2.2.1.5 Preparation of chemically competent E.coli cells 
O. The ligation was incubated overnight at 14°C. 
E.coli cells were streaked on LB plates and incubated at 37°C for 24h. A single 
colony was then inoculated into 25ml of LB medium, then 5ml of the  overnight 
incubated culture was added to 500ml of SOB medium and incubated at 37°C until 
the absorbance at 600nm reached 0.5-0.55. The culture was chilled on ice for 2h and 
the cells were collected by centrifugation at 2,500 x g for 10min at 4°C in a Sorvall 
RCB4 rotor. The cells were then resuspended in 100ml of ice-cold TB buffer and the 
cell suspension was incubated on ice for 10min. The mixture was centrifuged at 1800 
x g for 10min at 4°C. The cell pellet was resuspended in 18.6ml of TB buffer and 
1.4ml DMSO. The cells were either used immediately or 1ml aliquots were snap-
frozen in liquid nitrogen and stored at -80°C until use. 
2.2.1.6 Preparation of electro competent AGLO cells 
AGLO cultures were streaked on LB medium plates and incubated at 28°C for 24h, 
one single colony was picked from the fresh plate and inoculated into 10ml LB liquid 39 
 
and cultured at 28°C for 1d on shaker (225rpm). A 10ml AGLO cell culture was 
inoculated into 500ml of LB liquid and incubated at 28°C on shaker (225rpm) till OD 
was  over 0.5. The flask was chilled in ice  water for 20min  and centrifuged at 
4000rpm for 15min at 4°C (2x250ml).The supernatant was removed and cells were 
re-suspended in 250ml sterilized cold water, centrifuged as before. The supernatant 
was removed again and cells  re-suspended in 100ml sterilized cold water, then 
centrifuged as before.  The supernatant was removed and cells  re-suspended with 
10ml sterilized 10% cold glycerol and centrifuged. The supernatant was removed and 
the pellet was re-suspended with 1ml sterilized 10% cold glycerol. Fifty µl aliquots 
were snap frozen in liquid nitrogen and stored at -80°C for further use. 
2.2.1.7 Transformation of bacterial cells 
2.2.1.7.1 E.coli cells 
Aliquots of competent cells were thawed on ice, and 1μl of the ligation reaction was 
added to 200μl of competent cells in a 1.5ml microcentrifuge tube. The cells were 
mixed by pipetting, and incubated on ice for 20min. To perform the transformation, 
competent cells were transferred to a 42°C water bath for 45-60sec. Transformations 
were incubated on ice for 2min, then 1ml of LB broth was added. Transformants were 
allowed to recover at 37°C for 1h at 225rpm. The mixture was centrifuged at 
3000rpm for 5min, the supernatant was discarded and the cell pellet was resuspended 
in 100μL LB medium. The whole transformation culture was plated onto LB agar 
containing the appropriate antibiotic (kanamycin/ampicillin) and incubated overnight 
at 37°C. 
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2.2.1.7.2 Agrobacterium tumefaciens cells 
50µl of AGLO competent cells were thawed on ice for 5min, 1µl purified plasmid 
was transferred into the tube and gently mixed with pipette tip, then transferred the 
mixture into an ice-cold electroporation cuvette and incubated on ice for 2min and 
then electroporated using Bio-Rad Gene Pulsar set at 1.8kV and 2.5µFD and a Bio-
Rad Pulse Controller set at 200Ω.  Cells were resuspended in 500µl SOC media and 
incubated for 1h at 28°C with shaking. Cultures were spread onto LB agar plates 
containing appropriate antibiotics and incubated at 28°C for 48-72h. 
2.2.1.8 Screening of bacterial transformants for inserts 
Recombinants clones were selected by blue/white screening. Transformants were 
selected on LB plates having ampicillin (100μg/ml), 5-bromo-4-chloro-3-indoly-B-D-
galactopyranoside (X-gal) and isopropyl-B-D-thiogalactoside (IPTG). LB/ampicillin 
plates were spread with 30μL of X-gal (50mg/ml)
 
2.2.1.9 Preparation of glycerol stock 
and 100μL of 100mM IPTG and 
the  plates incubated at 37°C for 30min before plating transformants. Plates were 
incubated overnight at 37°C. Clones that contained insert generally produce white 
colonies. These were chosen to carry out either PCR analysis or analyzed by an 
appropriate restriction enzyme to confirm the presence of inserts. 
Bacterial glycerol stocks  were  prepared by mixing equal volume of overnight 
bacterial culture and 30% sterile glycerol, snap frozen in liquid nitrogen and stored at 
-80°C. 
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2.2.1.10 Isolation and purification of plasmid DNA 
Plasmid  DNA was isolated from E.coli  cultures using an  alkaline lysis protocol 
(Sambrook et al., 1989) . A single colony was inoculated into 4-5ml of LB liquid 
medium having appropriate antibiotics and incubated overnight with shaking at 37°C. 
A 1.5ml aliquot of the culture was centrifuged at 20,000 x g for 1min at room 
temperature and the pellet was resuspended in 100µl of ice cold Solution A (50mM 
glucose, 10mM EDTA, 25mM Tris-Hcl, pH 8) and 2µl of RNase was added. Bacteria 
was lysed by the addition of 150µl of freshly prepared Solution B (0.2M NaOH, 1% 
SDS) and mixed by gentle inversion. Chromosomal DNA and proteins were 
precipitated with 200µl of cold Solution C  (prepared by mixing 60ml of 5M 
potassium acetate solution, 11.5ml glacial acetic acid and 28.5ml of H2
2.2.1.11 Determination of DNA concentration 
O) and kept 
on ice for 5min. Plasmid DNA was separated from precipitated contaminants by 
centrifuging at 20,000 x g for 10min. the supernatant was collected in a fresh tube and 
plasmid DNA was precipitated by addition of 2 vol of ice cold 100% ethanol, mixed 
by inversion and kept at -20°C for 1-2h, followed by centrifugation at 20,000 x g for 
10min. The supernatant was discarded and DNA pellets were washed with ice-cold 
70% ethanol before being resuspended  in 30μL  of water.  Plasmid DNA to be 
sequenced was isolated using a Miniprep plasmid purification kit (Qiagen) according 
to the manufacturer’s protocol. 
The concentration of DNA was determined by O.D. measurements at 260nm and 
280nm using a  NanoDrop® ND-1000 Spectrophotometer  (Biolab)  and then 
converting to DNA concentration using the ratio 1.0 O.D. equal to 50μg/ml.  42 
 
2.2.1.12 DNA sequencing  
Sequencing was carried out using the Taq DyeDeoxy™ Terminator Cycle 
Sequencing Kit from Applied Biosystems Industries (ABI) using BigDye™ 
Terminator Cycle Sequencing chemistry. Sequencing reactions were half the volumes 
recommended by the manufacturer and consisted of 300-800ng of plasmid DNA 
added to 4.0μl of Terminator Ready Reaction Mix, 3.2pmol of primers, made to a 
final volume of 10μl  with  sterile  distilled  water  in  a  0.2ml  microfuge  tube.  The 
reactions were incubated in a Perkin Elmer Thermal Cycler 2400 at following cycling 
conditions: 
96°C     2min  
96°C     15sec 
50°C     5sec  
 60°C    4min 
25 cycles 
2.2.1.13 Purification of sequencing products 
Sequencing products were briefly centrifuged and transferred into a 0.5ml centrifuge 
tubes containing 2.5 vol of 100% ice cold ethanol and 0.1 vol of 3M NaOAc, pH 5.2 
after the PCR sequencing reaction. The mixture was vortexed briefly, kept in ice for 
20min and followed by the precipitation of DNA at 20,200 x g for a further 30min, 
then washed with 125μL of 70% ice cold ethanol at 20,200 x g for 5min and dried in 
a Speed-vac. Sequences were processed by Ms Frances Brigg (SABC) on an ABI 
3730 DNA Sequencer. 
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2.2.2 Extraction of genomic DNA from tobacco leaves 
Tobacco leaves were ground to a fine powder in liquid nitrogen using a mortar and 
pestle. The tissue were transferred to a tube of suitable size and 1ml of extraction 
buffer (2%w/v) hexadecyltrimethylammonium bromide (CTAB), 100mM Tris-HCL, 
1.4mM NaCl, 20mM EDTA) per gram of tissue was added. This was mixed by gentle 
inversion and heated at 55°C for 20min, followed by centrifugation at 15000 x g for 
5min. The supernatant was transferred to a fresh tube, one volume of chloroform: 
isoamyl alcohol (24:1) was added and mixed  by gentle  inversion for 2min  and 
centrifuged at 15000 x g for 20sec. The upper aqueous phase was transferred to a 
fresh tube and 1/10 volume of 7.5M ammonium acetate and two volumes of ice-cold 
ethanol was added. This was mixed by gentle inversion and placed in a freezer at -
20°C for 60min, then centrifuged at 1500  x  g for 1min and the  supernatant was 
discarded. The pellet was washed twice with 70% (v/v) ethanol and mixed each time 
by gentle inversion. The DNA was dried in a desiccator and resuspended in an 
appropriate volume of TE buffer. 
2.2.3 Agarose gel electrophoresis  
All agarose gel electrophoresis procedures were carried out in Bio-Rad Mini Sub™ 
cells or Bio-Rad Wide Mini Sub™ cells. 1X TAE buffer as described by (Sambrook 
et al., 1989) was used for electrophoresis. Depending on the size of DNA fragments 
of interest, agarose gels at concentrations between 0.8-1.8% was used. DNA 
fragments were mixed with loading dye and stained with either ethidium bromide or 
SYBR green. Gels were electrophoresed at a constant voltage (70-100V) until the 
loading dye had migrated between half and two thirds of the way down the gel. Gels 44 
 
were visualized either with a UV or Dark Reader transilluminator. Molecular weight 
markers used included 1kb DNA marker and 100bp DNA ladder. 
2.2.4 DNA purification 
2.2.4.1 Purification of DNA from agarose gels 
The Wizard SV gel and PCR clean-up system (Promega, USA) was used to extract 
and purify DNA from standard or low-melt agarose gels. The DNA fragment was 
excised from the gel using a clean scalpel and transferred to microcentrifuge tube. 
Membrane binding solution was added to a ratio of 10μL of solution per 10mg of 
agarose gel slice followed by incubation at 50-60°C until the gel slice was completely 
dissolved. A SV column was placed in a collection tube and dissolved gel mixture 
was added to the column followed by incubation at room temperature for 1min. The 
SV minicolumn was centrifuged at 16,000 x g for 1min and liquid in collection tube 
after centrifugation was discarded. The column was washed by adding membrane 
wash solution (700μL)  and  centrifuged  at  16,000  x  g  for  60sec.  Washing was 
repeated again by adding 500μL of buffer and centrifugation was performed at 16,000 
x g for 5min. The collection tube was then emptied and the column was recentrifuged 
for further 1min. After this, the minicolumn was transferred to a clean 1.5ml 
centrifuge tube and the DNA eluted with 50μL of sterile distilled water. After leaving 
to stand for 1min, the column was centrifuged for 1min to ensure complete elution of 
DNA. 
2.2.4.2 Purification of PCR products 
PCR products were purified using the Wizard  SV gel and PCR clean-up system 
(Promega, USA). DNA was amplified using standard PCR conditions and was 45 
 
purified before cloning into the vector. 50µl of PCR product was aliquoted into a 
1.5ml eppendorf tube and equal volume of Membrane binding solution was added. 
Then, the same procedure described for purification of DNA from agarose gel was 
followed. 
2.2.5 Agrobacterium mediated tobacco leaf-disc transformation 
A LB (plus appropriate antibiotic) agar plate was inoculated with a frozen stock of 
AGLO containing the appropriate Ti vector and incubated at 28°C for 2d. One single 
colony was picked from this plate and inoculated into 10ml of LB liquid plus 
appropriate antibiotic, grown for  2d  to OD600 of 0.6-0.8. Then cell culture was 
transferred into 10ml centrifuge tube and  centrifuged  for 15min at RT, then 
resuspended with 25ml fresh LB liquid medium, and transferred into 50ml tube and 
cultured at 28°C to OD600 of 0.6-0.8. About 50 leaf discs (5-10 x 5-10mm) from in 
vitro cultured young tobacco leaves (about 5-7 leaf stage) were cut into CM1 liquid 
medium and transferred into the 25ml Agrobacterium cell culture and incubated for 
10min with occasional swirling. Leaf discs were blot-dried on sterilized filter paper 
and transferred onto CM1 solid medium with top side down. The Petri dishes were 
sealed with parafilm and incubated at 25°C in a tissue culture room for two days. 
After that, the leaf discs were washed in CM1 medium with timentin (200mg/L) to 
kill the Agrobacterium, blot dried on filter paper and transferred onto SM1 medium 
with appropriate antibiotics, the plates were sealed with parafilm and placed back to 
the tissue culture room. The leaf discs were examined once or  twice a week for 
contamination. After 1-2 weeks, callus growth was noticed at the rims of the leaf 
discs. The leaf discs were transferred onto new SM1  medium with appropriate 46 
 
antibiotics after two  weeks. Within 3-4 weeks, tiny, green shoots were observed 
whereas the rest of the discs  were  bleached. 10-15mm long healthy shoots were 
transferred to SM2 medium with appropriate antibiotics to allow the transformed 
shoots to regenerate roots. Tobacco plants were subcultured to RM medium. 
2.2.6 GUS expression analysis  
2.2.6.1 Histochemical GUS Assay 
Tobacco cells were assayed  histochemically for GUS expression by  5-bromo-4-
chloro-3-indolyl-β-glucuronide  as  substrate and incubated overnight at 37°C as 
described by Jefferson (1989). Cells were destained in 70%  ethanol to remove 
pigmentation prior to being photographed. 
2.2.6.2 Fluoremetric GUS Assay  
β-glucuronidase (GUS) encoded by the gus  gene  catalyses  a  hydrolysis  of  β-
glucuronides into glucuronic acid and the other component of the moiety. The 
fluorimetric assay is based upon the hydrolysis of 4-methyumbelliferyl glucuronide 
(MUG), a non-fluorescent substrate, to glucuronic acid and 4-methylumbelliferone 
(4MU), a fluorescent product that can be quantified by fluorometry at 455nm. 
Explants weighing about 100mg were placed in 1.5ml Eppendorf tubes to which was 
added 0.5ml of GUS extraction buffer containing 50mM Na-phosphate buffer pH 7, 
10mM EDTA, 0.1% Triton 100, 0.1% sarkosyl and 10mM β-mercaptoethanol (in the 
fume  hood)(Sambrook et al., 1989).  Explants were then homogenized by sonication 
(model XL 2015, Misonix incorporated) for 10sec at 75% per second of ‘pulsar duty’ 
cycle. The cell debris was pelleted by centrifugation at 8000rpm for 5min at 4
0C then 
kept on ice. Extracted lysate (40μl) was added to 460μl of GUS extraction buffer 47 
 
containing 1mM MUG and incubated at 37
0C. Forty µl of mixture was withdrawn at 
time 0 and added to 140μl of 0.2M Na2CO3 to stop the enzyme activity. Samples 
(40μl) were taken every 30min for 3h to determine the enzyme activity over that 
period. The amount of fluorescence emitted from serially diluted  4-MU  standard 
solution treated with the same conditions as the test samples were read and used to 
plot a standard curve. From the standard curve, the fluorescence units of samples 
were converted to concentration of 4-MU and the specific GUS activity expressed as 
amount of 4-MU (pmoles) formed per min per 40μl of plant extract. 
Total proteins from plant extracts were quantified with Bradford’s reagent (Bradford, 
1976). 40µl of the remainder of the plant extract was added to 50μl of Bradford’s 
reagent and mixed. The OD of the samples was measured at 595nm after 15min 
incubation at room temperature. A standard curve was plotted from OD595 read of a 
serial dilution of BSA. The OD595
2.2.7 Plant RNA extraction 
  measurement of the sample was converted to 
concentration of protein (mg) using the standard curve and the specific GUS activity 
was calculated per mg protein. 
Total Plant RNA was isolated from tobacco leaves using the RNeasy Plant Mini Kit 
(Qiagen) and carried out using manufacturer’s protocol. To eliminate the possibility 
of  DNA contaimation from the RNA samples, the ‘optional’  on-column DNase 
digestion was followed. DNA contamination can result into a false positive result. 
2.2.8 Extraction and quantification of total soluble protein  
One gram of tobacco leaf material was ground in liquid nitrogen and homogenised in 
liquid extraction buffer (100mM Tris-Cl, pH 8.0, 150mM NaCl, 0.1% diethyl 48 
 
ammonium dithiocarbamate (DIECA), 2% polyvinylpyrrolidone (PVP), 1mM 
phenylmethylsulfonyl fluoride (PMSF), 10µg/ml leupeptin (Sigma), 0.05% plant 
protease inhibitor cocktail (Sigma) and 1% Na-deoxycholate). The tissue homogenate 
was centrifuged at 15,000 x g for 30min to remove soluble debris. Total proteins from 
plant extracts were quantified with Bradford’s reagent (Bradford, 1976). 
2.2.9 SDS-PAGE 
Aliquots containing 100µg of total soluble protein of transgenic and non-transgenic 
plants  were electrophoresed on SDS-PAGE using a resolving gel (12.5% [w/v]) and 
a stacking gel (4% [w/v]) in a Mini Protean gel system (BioRad) as described by 
(Laemmli, 1970) for 54min at 200V with a running buffer containing 25mM Tris, 
192mM glycine and 1% [w/v] SDS. Precision Plus (BioRad) 100kDa molecular 
weight markers (5µL per lane) were added in the marker lane and the extracts (diluted 
1:1 in 2X loading buffer) were loaded into single wells. Gels were then either stained 
with Coomassie Brilliant Blue or blotted onto nitrocellulose membrane. Gels were 
stained with 50ml of Coomassie Brilliant Blue stain (45% [v/v] methanol, 45% [v/v] 
distilled water, 10% [v/v] glacial acetic acid and 0.05% [v/v] Coomassie Brilliant 
Blue) overnight at room temperature on a horizontal rocker. The excess stain was 
removed using a de-staining solution (40% [v/v] methanol, 50% [v/v] distilled water 
and 10% [v/v] glacial acetic acid). De-staining solution was replaced at least twice 
until the gel was fully de-stained and gels were imaged with a Proxpress imaging 
system (Perkin Elmer). 
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2.2.10 Western Blotting  
After Electrophoresis the gel was transferred onto a nitrocellulose membrane in ice 
cold transfer buffer using Semi-Dry electrophoretic transfer cell (BioRad) at 20V for 
1h. The blotted membrane was then incubated for 1h at room temperature in blocking 
solution (5% skimmed milk powder in PBS-T) followed by 3 times washing with 
PBS-T for 5min on a horizontal rocker at room temperature and probed for 1h with 
appropriate primary antibody diluted 1:500 in 5% skimmed milk powder blocking 
solution.  The membrane was then washed again 3 times with PBS-T and further 
incubated with horseradish peroxidase (HRP) conjugated secondary antibody (1:2000 
dilution in 5% skimmed milk powder blocking solution) and agitated gently for 1h at 
room temperature. The membrane was washed 3 times with PBS, pH 7.4 before 
immersing in substrate solution (HRP color substrate (BioRad) 10mg, 16.6ml PBS 
pH 7.4, 3.325ml methanol and 10µl  of hydrogen peroxide) and the membrane 
developed in the dark for 1h at room temperature. The reaction was then stopped by 
washing with de-ionized water. 
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Chapter 3 
Introduction  of recombinant JDV Capsid-
Tranactivator of transcription (CA-Tat) and 
Surface Unit glycoprotein (SU) into tobacco 
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3.1 Introduction 
As described in Chapter 1, Jembrana Disease is endemic in Bali and the virus has 
subsequently been transmitted to Java, Sumatra and Kalimantan. Recombinant JDV 
capsid (CA), surface unit glycoprotein (SU) and Tat proteins expressed in E.coli have 
been analysed as potential vaccine candidates against Jembrana disease in Indonesia. 
JDV SU produced in the bacterial expression system did not induce any protective 
immune response against the virus. This might be due to lack of post translational 
modification in the bacterial expression system (Ditcham, 2007). Cattle vaccinated 
with the fused JDV CA and Tat vaccine developed a higher antibody titre against 
both antigens CA and Tat compared with responses  in cattle vaccinated with 
individual CA and Tat antigens detected by ELISA and western blot. A strong IgG, 
IgA and IgM antibody response was observed, but vaccination did not reduce any 
plasma virus load (Lewis, 2008).  
In this project, transgenic plants were used to produce JDV fused CA-Tat and SU and 
analysed for protein expression. There are a number of potential advantages of using 
recombinant protein produced in plants as vaccines. They do not require  a 
fermentation control system and can provide an adequate system for oral delivery of 
recombinant immunogens, they are cost effective, easy to scale-up and safer than 
conventional vaccines produced in animal cell culture (Table 3.1). Further discussion 
on these aspects is provided in Chapter 5. 
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Table 3.1 Comparison of features of recombinant protein production in different 
systems (Ma et al., 2003, Chu and Robinson, 2001, Houdebine, 2000) 
 
System  Overall 
cost 
Scale-up 
capacity 
Product 
quality  Glycosylation  Storage cost 
Bacteria  Low  High  Low  None  Moderate 
Yeast  Medium  High  Medium  Incorrect  Moderate 
Mammalian 
cell culture  High  Very low  Very high  Correct  Expensive 
Transgenic 
animals  High  Low  Very high  Correct  Expensive 
Plant cell 
culture  Medium  Medium  High  Minor 
differences  Moderate 
Transgenic 
plants  Very low  Very high  High  Minor 
differences  Inexpensive 
 
 
In this chapter, cloning and sub cloning of JDV fused CA-Tat and SU gene into a 
plant transformation vector JFH2 (kindly provided by Muhammad Theseen, Dept. of 
Genetics, University of Melbourne) is described. The reporter gene gfp was replaced 
by the gene of interest (CA-Tat/SU) in JFH2. Binary vector JFH2 contains the bar 
gene for selection of transformed cells.  The  bar  gene encodes the  enzyme 
phosphinothricin acetyl transferase (PAT) which detoxifies glufosinate by causing 
acetylation of the amino group. A flow diagram showing the overall plan is provided 
in Figure 3.1.  
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Figure 3.1  A  flow diagram showing the  steps undertaken in this project, same 
methodology was followed for SU. 
CA-Tat  CaMV35S 
Agrobacterium mediated 
transformation into tobacco 
plants 
JFH2  
(Binary vector) 
Selection and confirmation of transgenic plants 
Isolation of proteins from transgenic plants 
Western immunoblot/Dot blot/ RT-PCR for detection of 
mRNA and target proteins 
CaMV35S  Bar 
CA-Tat 
CA-Tat      pGEM-T 54 
 
 
Plant transformation was done using A. tumefaciens. Agrobacterium mediated gene 
transfer has been utilized for many years to generate stably transformed plants. This 
involves the transfer of the T-complex (a complex of the bacterial T-DNA and 
virulence gene products) from Agrobacterium to plant cells (Figure 3.2). Any DNA 
located between the 25bp direct repeats (left and right borders), which delimit the 
single-stranded T-DNA, is transferred into the plant-cell nucleus (Zupan et al., 2000) 
where it integrates into the plant chromosome via illegitimate recombination (Somers 
and Makarevitch, 2004). 
 
Figure 3.2  A schematic representation of Agrobacterium mediated plant 
transformation. Adapted from (Tzfira and Citovsky, 2006); for description see text. 55 
 
The transformation process consists of 10 major steps (Figure 3.2) - (1) it starts with 
recognition and attachment of the Agrobacterium  to the host cells, and the 
Agrobacterium  VirA/VirG signal transduction system senses the specific plant 
signals such as syringone and acetylsyringone in step 2. Activation of vir gene region 
then takes place (3), which is followed by formation of a T-DNA mobile copy by the 
VirD1/D2 protein complex (4). Then this immature T-complex (VirD2-DNA 
complex), together with other Vir proteins are delivered into the host cell cytoplasm 
(5) and in step 6, VirE2 binds to the T-strand and the mature T-complex forms which 
travels through the host cell cytoplasm and is then actively imported into the host cell 
nucleus  (7). Once  inside the nucleus, the T-DNA is recruited to the point of 
integration (8), escorting proteins are stripped off (9) and the T-DNA is integrated 
into a host cell chromosome in the final step (Tzfira and Citovsky, 2006). 
Putative transgenics generation (T1) produced in this project were analysed by the 
following methods: PCR to detect the presence of transgene; semi quantitative RT-
PCR to detect the presence of transcripts; Dot- blot and western blotting to check for 
protein expression. 56 
 
3.2 Materials and methods 
3.2.1 Procurement of clones  
Plasmid DNA containing JDV CA-Tat-GST in pGEX-6-PI and JDV 3886bp genome 
(nt3847-7732) in pT7T3 were kindly provided by Dr. Moira Desport (School of 
Veterinary & Biomedical Sciences, Murdoch University) and used to amplify CA-Tat 
and SU sequences respectively. 
3.2.2 Amplification of JDV CA-Tat/SU 
The JDV CA-Tat was amplified by PCR using JCAF and JTatR primers (Table 3.2) 
using the following PCR conditions: 94°C for 5min followed by 30 cycles of 94°C 
for 30sec, 50°C for 50sec, 72°C for 1min and a final elongation step of 10min at 
72°C. JDV SU was amplified using the following thermal cycler conditions: 94°C for 
5min followed by 30 cycles of 94°C for 30sec, 55°C for 45sec, 72°C for 1min 20sec 
and a final elongation step of 10min at 72°C, using primers JSUF and JSUR (Table 
3.2). The amplified products were separated by electrophoresis in 1 % agarose gel.  
3.2.3 Plasmid constructs for leaf disc transformation 
PCR products were purified using a Wizard PCR clean-up system (Promega) and 
ligated into pGEM-T according to the conditions described in Chapter 2. Half (10µl) 
of the ligation mix was used for transformation of E.coli cells and plated on LB 
containing ampicillin (50µg/ml), X-Gal and IPTG for blue/white screening. 
Transformed cells were then grown at 37°C overnight and inserts confirmed by 
restriction digestion using EcoR1. Sequencing was done using T7 and SP6 primers 
(Table 3.2). Clones containing CA-Tat were amplified using primers 9 and 10 (Table 
3.2) having SpeI and XbaI restriction sites respectively using an initial denaturing 57 
 
Table 3.2 Primers used for amplification and construction of the recombinant 
plasmids and sequencing 
No.  Primer  Primer sequence (5′ → 3′)  Annealing 
temp.(°C) 
1.  JCAF  CCCACAATTAGAAAGAAC  43 
2.  JTatR  TCACGCGCAGTTAGGTGC  56 
3.  JSUF  GACATGATGGAAGAAGGAAG  58 
4.  JSUR  GGCTCTCTTTCCCTAGG  58 
5.  T7  TAATACGACTCACTATAGGG  48 
6.  SP6  CATACGATTTAGGTGACACTATAGA  53 
7.  JFHF  CATCACGCCATGGTCGACG  55 
8.  JFHR  GATGGTGATGCATTCCCGGG  56 
9.  CTSpeF  GGACTAGT 60  *CCACAACTTAGAAAGAACTCC 
10.  CTXbaR  GCTCTAGA 59  *TCACGCGCAGTTAGGT 
11.  SUSpeF  GGACTAGT 56  *ATGATGGAAGAAGGAAG 
12.  SUXbaR  GCTCTAGA 57  *CTCTCTTTCCCCTAG 
13.  RTCTF  ACCACCCAAGAATGCAGAGACACT  57 
14.  RTCTR  TTGGTAGTTTCGGGTGCTGCCATA  57 
15.  RTSUF  TTAGCAATGCTCCCATACCCGACT  57 
16.  RTSUR  CTGTTTGCATCTAAGCGGGCCAAT  57 
*restriction enzyme site included 
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 step for 5min at 94°C, followed by 30 cycles of 94°C (30sec), 58°C (50sec), 72°C 
(1min) and a final elongation of 10min at 72°C. SU was amplified using primers 11 
and 12 (Table 3.2) having SpeI and XbaI restriction sites. PCR was carried out with 
following conditions:  initial denaturing step for 5min at 94°C, followed by 30 cycles 
of 94°C (30sec), 55°C (50sec), 72°C (1min) and a final elongation of 10min at 72°C. 
PCR products were separated on 1% agarose gel and the desired DNA fragments 
were eluted from the gel using a Wizard SV gel clean up system (Promega), and 
cloned into plant transformation vector JFH2. Both the purified PCR product and 
JFH2 was digested with SpeI and XbaI. CA-Tat/SU DNA were then ligated with 
digested  JFH2  (Figure  3.3) overnight at 14°C. 15µl of ligation mix was used to 
transform chemically competent E.coli  cells and plated on LB plates containing 
kanamycin (50µg/ml) and grown overnight at 37°C. Plasmid isolation was carried out 
using a QIAprepspin kit (Qiagen). PCR was done using plasmid specific primers 
JFHF and JFHR (Table 3.2) under the following thermocycler conditions: 94°C for 
5min followed by 35 cycles of 94°C for 30sec, 58°C for 40sec, 72°C for 1min and a 
final elongation step of 10min at 72°C. The amplified products were electrophoresed 
on  agarose gel and  PCR products  were  purified using the  Wizard  PCR clean-up 
system (Promega). Sequencing was done to confirm that the correct insert  was 
present. 59 
 
 
Figure 3.3 Map showing plant transformation vector JFH2 harbouring the SU gene 
(blue). 
 
3.2.4 Tobacco transformation  
The plasmids JFHCA-Tat/JFHSU containing CA-Tat and SU genes were prepared 
from cultures of E.coli and transformed into A. tumefaciens AGLO as described in 
Chapter 2. Agrobacterium mediated transformation of tobacco leaf discs was done 
using the method described in Chapter 2. Explants were transferred on SM1 medium 
containing 20mg/l glufosinate two days after incubating on co-cultivation medium. 
SM1 medium was changed after every two weeks until shoots were emerged and then 
shoots were transferred to rooting medium containing 20mg/l glufosinate.  
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3.2.5 Screening of T0 
Genomic DNA was isolated from plants using the CTAB method as described in 
Chapter 2. To confirm the presence of the CA-Tat/SU gene in the plantlets, PCR was 
carried out using plasmid specific primers JFHF and JFHR (Table 3.2). PCR products 
were separated by 1% agarose gel electrophoresis and the DNA fragment encoding 
CA-Tat/SU was eluted from the gel using Wizard SV gel clean up system (Promega) 
and sequencing was done as described in Chapter 2.  Transgenic plantlets (T
plants 
0 
generation)  were then transferred to  a PC2  glasshouse  and grown  for seeds  (T1
3.2.6 Molecular analysis of T
 
generation). 
1
Seeds of T
 plants 
0
3.2.6.1 PCR analysis  
 plants were then grown in the PC2 glasshouse for the molecular analysis 
described below. 
Total DNA was isolated from tobacco leaves using the CTAB method described in 
Chapter 2 and PCR was carried out using JFH and JFHR primers (Table 3.2) to 
confirm the presence of CA-Tat  or SU gene. PCR positive plants were then 
transferred to individual pots for further analysis. Five different plants per transgenic 
event were used for protein analysis for each construct. 
3.2.6.2 RNA isolation 
Total RNAs were isolated from tobacco leaves (80-100mg) using a Qiagen RNeasy 
Plant Mini Kit according to manufacturer’s instructions. 
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3.2.6.3 RT-PCR 
MuLV Reverse Transcriptase (Applied Biosystem) was used for cDNA synthesis and 
RT-PCR was carried out by following the manufacturer’s protocol. Reactions were 
carried out in thermal cycler with following conditions: 25°C for 10min, 37°C for 
90min and 85°C for 5sec. Concentration of cDNA was determined in 1µl aliquots 
using a nanodrop spectrophometer. PCR was carried out using primers 11 and 12 or 
13 and 14 (Table 3.2) specific for CA-Tat and SU respectively, under the following 
conditions: 94°C for 5min followed by 30 cycles of 94°C for 40sec, 55°C for 30sec, 
72°C for 30sec and a final elongation step of 5min at 72°C.  
3.2.6.4 SDS-PAGE 
Total soluble protein was extracted from tobacco leaves using the method described 
in Chapter 2. Total soluble proteins (100µg sample loaded per lane) were separated 
on 12.5% SDS-polyacrylamide gel which were subsequently  either stained with 
Coomassie Brilliant Blue or blotted onto nitrocellulose membrane as described in 
Chapter 2. 
3.2.6.5 Western Blotting 
Proteins  separated on SDS-PAGE were electrophoretically transferred to 
nitrocellulose membrane and then blocked with 5% skimmed milk in PBS-T to 
prevent non specific antibody binding. The membrane was probed with monoclonal 
antibody against JDV CA (1:500 dilution) and polyclonal antibody for SU (1:500 
dilution)  respectively (kindly provided by Dr. Moira Desport, School of Veterinary 
& Biomedical Sciences, Murdoch University). Following this, the membrane was 
incubated with secondary antibody (rabbit anti-bovine IgG for CA-Tat and goat anti-62 
 
mouse IgG for SU) conjugated to HRP (1:2000 dilution) and developed using HRP 
substrate (Biorad) solution as described in Chapter 2.  
3.2.6.6 Dot Blot  
Leaves of transgenic and non transgenic tobacco plants were squashed onto 
nitrocellulose membrane using small plastic pestles and total soluble protein was also 
directly blotted on the membrane. Membranes were dried at room temperature and 
blocked with 5% (w/v) skim milk powder in PBS-T. Membranes were then probed 
with appropriate antibodies as described above for western blotting. 63 
 
3.3 Results  
3.3.1 Amplification of CA-Tat and SU   
JDV CA-Tat (Figure 3.4) and SU (Figure 3.5) genes were amplified using primers 1 
and 2 or primers 3 and 4 respectively (Table 3.2). The amplified products were 
analysed by gel electrophoresis to ensure correct amplification of the 967bp (CA-Tat) 
fragment and 1266bp (SU) fragment before being ligated into the cloning vector 
pGEM-T Easy. 
 
Figure 3.4 Agarose gel electrophoresis of the CA-Tat amplified using primers 1 and 2 (Table 
3.2). Lane 1, 100bp DNA ladder; lane 2, CA-Tat; lane 3, negative control. 
 
 
 
Figure 3.5 Agarose gel electrophoresis of the PCR product of primers 3 and 4 (Table 3.2) 
showing SU fragment. Lane 1, 1kb DNA ladder; lane 2, SU plasmid 55; lane 3, SU plasmid 
195; lane 4, negative control. SU plasmid 195 was used for subsequent cloning experiments. 
 
 
             1                 2                  3 
      1         2            3           4 
967 bp 
1266 bp 
500 bp 
1kb 64 
 
3.3.2 Cloning of CA-Tat/SU into pGEM-T and binary vector JFH2  
PCR products were eluted from the gel and ligated into pGEM-T Easy vector by TA 
cloning (Figure 3.6). Plasmid DNA was isolated from recombinant clones and the 
correct sizes confirmed by PCR. 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
         
 
 
 
Figure 3.6 Schematic representation of cloning of CA-Tat/SU into pGEM-T Easy 
vector, and transformation into E.coli. 
MCS: Multiple cloning site 
 
 
PCR was done using CA-Tat (Figure 3.7) and SU (Figure 3.8) specific primers. The 
amplified products were visualised with 1% agarose gels. The specificity of the 
clones was confirmed by PCR followed by sequencing. 
MCS  MCS  T7  SP6  lacZ  lacZ 
CA-Tat/SU 
Ligation 
pGEM-T Easy Vector 
MCS  MCS  CA-Tat/SU  SP6  lacZ  T7  lacZ 
Recombinant vector in E.coli 
 
 
 
Transformation into E.Coli 
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Figure 3.7 Gel electrophoresis of PCR product of pGEM-T having CA-Tat (967bp) 
generated with primers 1 and 2 (Table 3.2). Lane1, 1kb DNA ladder; lane 2-4, 
pGEM-T containing the CA-Tat gene; lane 5, positive control; lane 6, negative 
control.  
 
 
 
 
 
Figure 3.8 Gel electrophoresis of PCR products of pGEM-T having SU (1266bp) 
generated with primer 3 and 4 (Table 3.2). Lane 1, 1kb DNA ladder; lanes 2-12, 
pGEM-T clones, all except lane 7 showing a fragment of 1267bp representing SU; 
lane 13, positive control; lane 14, negative control. 
 
pGEM-T containing CA-Tat or SU genes were amplified using primers 9 and 10 or 
11 and 12  (Table 3.2) with restriction sites SpeI and XbaI respectively.  
The amplified products were cloned into binary vector JFH2 under the transcriptional 
control of the CaMV35S promoter for constitutive expression in plants. PCR was 
done to confirm the presence of inserts in JFH2 using plasmid specific primers JFHF 
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and JFHR (Table 3.2) and the analysis demonstrated the presence of amplified 
products of the expected size (Figure 3.9). 
 
 
Figure 3.9 Visualisation of the PCR products cloned into the binary vector JFH2 
generated with primers 7 and 8 which were designed in the flanking region of gfp 
gene (Table 3.2). Lane 1, 1kb DNA ladder; lanes 2-6, JFH2 clones having CA-Tat; 
lanes 7-11, JFH2 clones containing SU; lane 12, Untransformed JFH2 containing 
gfp gene; lane 13, negative control. 
 
 
3.3.3 Generation of transgenic tobacco plants 
Leaf-disc transformation of tobacco plants was carried out using A.  tumefaciens 
AGLO harbouring JDV CA-Tat/SU genes in vector JFH2 which also contain the bar 
selectable marker gene. To select transgenic plant tissues, leaf discs (Figure 3.10) 
were cultured at 20mg/L of glufosinate. Untransformed tobacco leaf discs were 
grown on the same regeneration and selection medium as controls. Transformed 
tissues showed normal leaf and root generation in the presence of glufosinate while 
no shoots developed on control discs. The transgenic plants did not show any 
morphological difference compared to non-transgenic tobacco plants. The selected 
plantlets  were  then  transferred to a  PC2 glasshouse.  
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Figure 3.10 A flow diagram showing the steps involved in generation of transgenic 
tobacco plants from leaf discs after co-cultivation with A.tumefaciens. 
 
After 2 days on co-cultivation medium (CM1), leaf disks 
were transferred to shoot regeneration medium (SM1) 
In 1-2 weeks, callus was observed and shoots were formed 
after 3-4 weeks 
Well developed shoots were then transferred to root 
formation medium (SM2) and kept for about 3 weeks 
The plantlets were then transferred to steamed soil in the 
PC2 glasshouse, and all flowering heads bagged to prevent 
any release of pollen 68 
 
3.3.4 Confirmation of putative transgenic lines 
To confirm that  putative transgenic plants  were transformed, DNA from selected 
tobacco lines was isolated and PCR assays were done with primers 7 and 8 (Figure 
3.11). CA-Tat and SU specific PCR products were detected in DNA extracted from 
transformed tobacco leaves as well as from the plasmid, whilst none was detected in 
control non-transformed leaves (sometimes a smaller non-specific band was also 
amplified)  
 
 
 
Figure 3.11 PCR products for SU and CA-Tat amplified from transgenic tobacco 
genomic DNA using primer JFHF and JFHR. Lane 1, 1kb  DNA ladder; lane 2, 
transformed tobacco line SU1; lane 3, SU24; lane 4, transgenic tobacco line CT5; 
lane 5, untransformed tobacco DNA; lane  6 &  7, JFH2 with gfp gene; lane 8, 
negative control. 
 
PCR was done on multiple samples and the presence of CA-Tat was confirmed in 12 
T0 plants and presence of SU was confirmed in 21 T0
Seeds from bagged heads of T
 plants. 
0 plants were collected and germinated in the PC2 
glasshouse. Genomic DNA was isolated from leaves of T1
           1              2                3              4              5              6             7                 8 
 plants and PCR was done 
using primers 7 and 8 to detect the presence of CA-Tat and SU. PCR positive plants 
were used for further molecular analysis. 
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The transgenic plant lines were named as follows: 
CT (Capsid Tat) 
SU (Surface glycoprotein) 
T0 event number (1-12 or 1-21) 
T1 line numbers (1.1-1.8) 
eg. CT2.1 defined capsid Tat transformed line, T0 event 2, line 1 at T1 
3.3.5 RT-PCR to study transcript expression  
from plant 2. 
Plants containing the SU gene are numbered in the same way eg. SU 8.6  
Using total plant RNA extracts, RT-PCR analysis was done to confirm the expression 
of CA-Tat/SU gene in the 4 selected transgenic plants identified as positive by PCR. 
The CA-Tat or SU specific fragments of the expected size (185bp for CA-Tat and 
175bp for SU) were amplified in the transgenic plants whilst they were absent in 
control plants. Semi quantitative RT-PCRs were performed with primers 13 and 14 
(Table 3.2) for CA-Tat (Figure 3.12) and 15 and 16 (Table 3.2) for SU (Figure 3.13). 
These results show that both of the genes were transcribed into mRNA and that there 
was no DNA contamination in the RNA extracts. 
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Figure 3.12 PCR from cDNA of CA-Tat transformed lines using primers 13 and 14 
(Table 3.2). Lane 1, 100bp DNA ladder; lane 2, CT2.1 cDNA; lane 3, CT2.1 RNA; 
lane 4, CT5.3 cDNA; lane 5 CT5.3 RNA; lane 6, CT6.1 cDNA; lane 7 CT6.1 RNA; 
lane 7, CT9.4 cDNA; lane 8, CT9.4 RNA; lane 9, Untransformed line cDNA; lane 10, 
Untransformed line RNA; lane 12, positive control; lane 13, negative control; lane 
14, 1kb DNA ladder (for abbreviation see 3.3.4). 
 
 
 
 
 
 
 
Figure 3.13 PCR from cDNA of SU using primers 15 and 16 (Table 3.2). Lane 1, 
100bp DNA ladder; lane 2, SU8.6 cDNA; lane 3, SU8.6 RNA; lane 4, SU14.5 cDNA; 
lane 5 SU14.5 RNA; lane 6, SU19.5 cDNA; lane 7 SU19.5 RNA; lane 7, SU25.2 
cDNA; lane 8, SU25.2 RNA; lane 9, Untransformed line cDNA; lane 10, 
Untransformed line RNA; lane 12, positive control; lane 13, negative control; lane 
14, 1kb DNA ladder (for abbreviation see 3.3.4). 
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3.3.6 SDS-PAGE of transgenic plant leaf extracts 
Protein extracts were prepared from T1
           
  leaves and the protein concentration was 
measured. SDS-PAGE gels were run and stained with Commassie Blue at room 
temperature overnight and then destained. The gel was recorded using the ProExpress 
imaging system (Figure 3.14). It was not possible to visualise the presence of the CA-
Tat protein as a new band in the transgenic lines. 
 
 
 
 
Figure 3.14  Commassie Blue stained SDS PAGE gel of total soluble proteins 
extracted from tobacco leaves. Lane 1, Protein marker; lane 2, purified CA protein; 
lanes 2-12, CA-Tat transformed tobacco lines; lane 13, untransformed tobacco line. 
 
Purified SU protein was not available for inclusion as a purified protein control lane, 
therefore similar results obtained for SU are not shown. 
3.3.7 Western blot analysis of total soluble protein extracts 
The plants that were found to be positive by PCR were analysed by western blotting 
(Figure 3.15) to check for specific expression of the transgenic protein. 100µg of total 
1     2      3         4      5        6      7      8       9      10     11    12    13 
75kDa
 
25kDa
 
Purified CA protein 72 
 
soluble protein from transgenic and non transgenic plant leaf tissues was separated by 
SDS-PAGE and blotted onto a nitrocellulose membrane. When the blots were probed 
with antibodies to visualise the location of any of the target proteins, the purified CA 
protein was readily detected in the purified control lane, but not in transgenic plant 
extracts. CA-Tat polyprotein was not detected in any of the transformed plants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 Western blot analysis to detect CA-Tat protein  Lane 1, Protein marker; 
lane 2, purified CA protein; lanes 2-12, CA-Tat transformed tobacco lines; lane 13, 
nontransgenic tobacco line. 
The same result was obtained for western blots of SU transgenic plants, but the result 
is not shown, because purified SU protein was not available as a positive control. 
3.3.8 Dot blots to check the expression in total protein extracts 
Because the western blots did not reveal the presence of expressed JDV protein in 
transgenic plants, dot blot analysis was undertaken of whole leaf samples in case the 
extraction procedure used for western blotting analysis had failed to extract the 
recombinant proteins. Dot blot analysis was done on leaves of transformed and 
untransformed plants (Figure 3.16). The results obtained were the same as those of 
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western blotting analysis. The positive CA-Tat control showed a purple stain, but not 
transgenic plant blots. No evidence for transgene protein expression was observed for 
any transgenic plant lines.  Similarly dot blots were undertaken for SU and no 
expression was detected in transformed lines. 
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Figure 3.16 Dot blots of transformed and untransformed lines. Leaf material was 
squashed into nitrocellulose membrane and probed with specific antibodies and then 
treated with HRP substrate solution. 
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3.4 Discussion  
In this chapter, cloning of the JDV genes CA-Tat and SU into tobacco was achieved 
successfully. T0 and T1 
3.4.1 Analysis of putative transgenic plants 
transgenic tobacco plants were generated which, according to 
RT-PCR analysis showed that the inserted genes were transcribed. However, attempts 
to demonstrate expression of the desired proteins, both in western blots of protein 
extracts and by dot blotting from whole leaf tissues, failed to provide evidence of 
expression of the protein in transgenic plants. 
Putative transformants were identified using PCR. Small scale DNA preps in 96 well 
plates using 100 mg of leaf tissue were initially used for DNA extraction from T1
3.4.2 Protein expression  
 
transgenic plants. However, consistent amplification of the required product was a 
problem. This was solved by doing further DNA extractions in 1.5 ml centrifuge 
tubes using a larger leaf sample. Results were more consistent with this preparation. 
Because of the expression results obtained, Southern blotting was not undertaken. 
This would have been done to provide insert copy number and clear evidence of 
inserts in high molecular weight DNA, which would also confirm that no 
Agrobacterium contamination had occurred. 
The PCR positive  T1  plants were analysed for the presence of the transgene 
transcripts and for protein expression. Transcript analysis was done by Reverse 
transcriptase-PCR (RT-PCR) and protein expression was analysed by western 
blotting and dot blot. Transgene transcripts were clearly present when assayed by RT-
PCR. However, no protein expression from the transgenes was detected, so there 75 
 
appeared to be a problem between transcription and translation of the transgene. This 
could possibly be due to post transcriptional or post translational processing and 
codon usage.  The expression of a particular heterologous gene and subsequent 
production of its protein in plant cells are influenced by various factors. These 
include (1) transcriptional factors such as transgene copy number and site of 
integration of the T-DNA in the chromosome; (2) post-transcriptional factors 
including mRNA splicing, 5´-untranslated leader (UTL), 3´-end formation, mRNA 
stability, and translation; (3) post-translational factors, for example protein stability 
and modification (Koziel et al., 1996, Gallie, 1998). 
Folding, assembly and post-translational modification are influenced by the 
subcellular environment where recombinant protein accumulates. Factors such as 
surrounding pH and presence of protease and chaperones can also affect transgenic 
stability of proteins. 
3.4.2.1 Codon usage in plants 
One of the factors that may reduce the level of gene expression of an animal virus 
protein in plants is codon usage. The pattern of codon usage in plants differs from 
that in animals. This difference in codon usage between the transgene and the 
expression host could well affect the expression level of heterologous proteins (Jamal 
et al., 2009). Regarding the expression of CA-TAT and SU genes in tobacco plants, 
differences in codon preference could reduce the level of expression and destabilise 
mRNA before translation.  Modification of the coding sequence of heterologous 
protein more closely to the host sequence may result in successful protein expression. 76 
 
Codon optimisation has been used to improve the recombinant protein expression in 
some reports (Perlak et al., 1991, Rouwendal et al., 1997, Suo et al., 2006). 
3.4.2.2 Post-transcriptional factors 
Post-transcriptional processing can have a major effect on the levels of a transgenic 
protein produced in the cells. This can also affect the transcript stability. The mature 
transcript has to be protected from premature degradation and transported efficiently 
to the cytoplasmic translational machinery. If this does  not occur efficiently, then 
post transcriptional processing  events like splicing, capping and polyadenylation 
could significantly reduce the expression of proteins in the plant cells (Gutierrez et 
al., 1999). 
3.4.2.3 Post-translational factors 
Although the protein synthesis pathway is highly conserved in plants and animals, 
there are some important differences in post-translational modifications (Figure 3.17).  
 
Figure 3.17 Complex long-chain glycan structures in plants and mammals. α (1,3) 
fucose and β (1,2) xylose residues are present only in plants whereas galactose and 
acetylneuraminic acid is found normally in mammals, not in plants (Saint-Jore-
Dupas et al., 2007). 
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These minor glycan structure differences could well alter the localisation, activity and 
longevity of recombinant proteins (Ma et al., 2003).  
The processses of protein degradation also affect if and how much a protein can 
accumulate in a plant cell. There are known systems like ubiquitination, which target 
proteins  for  degradation.  Ubiquitin-dependent proteolysis is the major protein-
degrading pathway in the cytoplasm of eukaryotic cells (Vierstra, 1993). Protein 
substrates for this pathway are marked by covalent attachment of ubiquitin, a small 
and highly stable protein. Several units of the small polypeptide ubiquitin get 
attached to the protein substrate and proteins carrying these residues are subsequently 
degraded by a specific protease, the 26 S proteasome (Coux et al., 1996, Jentsch and 
Schlenker, 1995).  There have been many examples which demonstrate that 
heterologous proteins can be degraded at rates which result in a significant reduction 
of end product level in the cell (Hoffman et al., 1988, Ohtani et al., 1991, Utsumi et 
al., 1993). 
Although the cloned genes CA-Tat and SU from JDV could be introduced into 
tobacco plants, and expression of their mRNA was confirmed, it was not possible to 
show production of the protein products. Post-transcriptional  or post-translational 
processing could be responsible for this lack of expression of the transgenic protein. 
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Chapter 4 
Investigating the potential function of a Porcine 
Circovirus (PCV) promoter in plants 79 
 
4.1 Introduction  
In parallel with the work to study expression of JDV proteins as antigens in plants, a 
study of the potential of a PCV promoter to drive gene expression in plants was 
undertaken. This was done so that if successful it could provide a novel plant 
promoter with freedom to operate to drive expression of JDV antigens in plants.  
The reasoning behind this work was that plant nanoviruses are remarkably similar to 
animal circoviruses in their genome organisations, and they were initially 
characterised as being in the same virus group, with some members that replicate in 
plants and in animal cells. Plant nanoviruses, such as BBTV, are single stranded 
DNA viruses that are multipartite, with a single gene per circular sub-genome and 
each promoter can act as a promoter in plant cells when cloned ahead of a gene of 
interest (Dugdale et al., 1998, Hermann et al., 2001). Since there are very few DNA 
viruses whose promoter can be used in this way, and all have foreign IP ownership, 
the potential for an animal circovirus promoter to act as a plant promoter is  an 
original concept. 
 PCV belongs to genus Circovirus  within the family Circoviridae.  Porcine 
circoviruses are isometric nonenveloped virus with the diameter of viral particles 
around 17nm. These are the smallest animal viruses capable of independent 
replication (Tischer et al., 1982). The rep gene is the largest ORF of PCV which 
encodes Rep protein. This protein is highly conserved in all circoviruses (Mankertz et 
al., 1998a). It shows homology to the sequence of Rep proteins of nanoviruses and 
geminiviruses and PCV potentially bridges the gap between animal and plant 80 
 
circoviruses. The rep gene promoter (Prep) resides on a fragment position 640-796 
and overlaps the intergenic region and origin of replication.  
As promoters affect transcription both qualitatively and quantitatively, success of 
expression using recombinant DNA technology depends on the particular promoter 
chosen.  
The strength and specificity of promoters is often tested by measuring the expression 
of a linked reporter gene such as gus. The Gus reporter gene is one of the most widely 
used reporter genes in plant molecular biology. The assay for the GUS protein that it 
encodes is straightforward, relatively inexpensive, sensitive, highly reliable, safe and 
can be visualised histochemically using the X-gluc substrate. The gusA, gene encodes 
the  enzyme  β-glucuronidase (GUS). This enzyme can cleave the chromogenic 
substrate X-gluc (5-bromo-4-chloro-3-indolyl  β-D-glucuronic acid)  (Figure  4.1), 
resulting in the production of an insoluble blue color in those plant cells displaying 
GUS  activity.  Tobacco  cells  themselves do not contain any GUS activity, so the 
production of a blue color when stained with X-gluc in particular cells indicates the 
activity of the promoter. 
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Figure 4.1 X-Gluc (5-bromo-4-chloro-3-indolyl-β-D-glucuronide), a substrate of β-
glucuronidase, is cleaved to produce glucuronic acid and chloro-bromoindigo. When 
oxidized, chloro-bromoindigo dimerizes to produce the insoluble blue precipitate 
dichloro-dibromoindigo 
(http://www.clfs.umd.edu/classroom/bsci415/straney/lab/transformation.html) 
 
The aims of the work (Figure 4.2) were as follows: 
1.  To amplify Porcine Circovirus (PCV) 156bp rep gene promoter using specific 
primers  
2.  To clone into pGEM-T and sequence the PCV promoter  
3.  To develop an expression gene cassette by replacing constitutive CaMV35S 
promoter of pCAMBIA1303 with PCV rep gene promoter in frame with gus 
(uidA). 82 
 
4.  To study the potential of expression of the reporter gene Gus  using 
histochemical and fluorometric GUS assay of transgenic plants generated 
contains the PCV promoter-gus construct. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 A flow diagram showing steps used in generating transgenic plants with 
PCV promoter-gus insert. 
PCV promoter 
PCV promoter 
pGEM-T 
PCV promoter  gusA  pCAMBIA1303 
Agrobacterium mediated transformation into tobacco plants 
Check the expression of gus by histochemical and fluorometric methods 83 
 
4.2 Materials and Methods 
4.2.1 Amplification of the PCV promoter  
PCV genomic DNA was kindly provided by Mark O’Dea (School of Veterinary & 
Biomedical Sciences, Murdoch University). Primers were designed to amplify the 
156bp  rep  gene promoter by aligning promoter region sequences  (Figure  4.3) of 
different PCV strains (sequences taken from NCBI). Sequences were aligned using 
programme MultiAlin (Multiple sequence alignment). 
 
 
 
 
 
 
 
Figure 4.3  A diagram showing PCV promoter region conserved sequences  in 
different PCV strains. 
 
The PCV promoter (156bp) was amplified using primers 1 and 2 (Table 4.1) which 
flank the 156bp region. PCR was done using the following cycling conditions: initial 
denaturing step for 3min at 94°C, followed by 5 cycles of 94°C (1min), 50°C (30sec), 
72°C (40sec), 25 cycles of 94°C (1min), 52°C (30sec), 72°C (40sec) and a final 
Start of PCV promoter 
PCV promoter end site 84 
 
elongation step of 72°C for 5min. 10µl of PCR product was then electrophoresed on a 
1.8% agarose gel. 
 
Table 4.1 Primers used to study PCV promoter expression 
 
No.  Primer  Primer sequence (5′ → 3′)  Annealing 
temp.(°C) 
1.  CirProF  TTCCTTCTCCARCGGTARCGGT  57 
2.  CirProR  GCTGCCGAGGTGCTGCCGCTG  64 
3.  CirpGemtF  AGGCATGCAAGCTT 60  *GCGGGGGT 
4.  CirpGemtR  GCTGCCCCATGG 62  *CTGCCGC 
5.  p1303F  TGTGGAATTGTGAGCGG  47 
6.  p1303R  AACGCTGATCAATTCC  41 
7.  T7  TAATACGACTCACTATAGGG  48 
8.  SP6  CATACGATTTAGGTGACACTATAGA  53 
R = AG, *restriction enzyme site included 
 
 
4.2.2 Cloning of the PCV promoter  
PCR products were purified using a Wizard PCR clean-up system (Promega) and 
ligated into pGEM-T according to conditions described in Chapter 2. Half (10µl) of 
the ligation mix was used for transformation of E.coli  cells and plated on LB 
containing ampicillin (50µg/ml), X-Gal and IPTG for blue/ white screening. The 
transformed colonies were grown at 37°C overnight and inserts confirmed by 
restriction digestion using EcoRI.  Sequencing was done using T7 and SP6 primers 
(Table 4.1). A clone containing 156bp PCV promoter was then amplified using 
primers 3 and 4 (Table 4.1) having NcoI and HindIII restriction sites respectively, 85 
 
using initial denaturing step for 5min at 94°C, followed by 30 cycles of 94°C (30sec), 
50°C  (45sec),  72°C  (50sec) and a final elongation of 10min at 72°C. The PCR 
products were separated on 1.5% agarose gel and 156bp DNA fragment was eluted 
from the gel using a Wizard SV gel clean up system (Promega) and cloned into 
pGEM-T as described above. Plasmid isolation was carried out using QIAprepspin kit 
(Qiagen). Both purified plasmid with the 156bp promoter fragment and the plant 
transformation vector pCAMBIA1303 were digested with NcoI  and  HindIII. 
Promoter DNA was then ligated with restricted pCAMBIA1303 in frame with β gus 
reporter gene (Figure  4.4) overnight at 14°C. 15µl of ligation mix was used to 
transform chemically competent E.coli  cells and plated on LB plates containing 
kanamycin (50µg/ml) and grown overnight at 37°C. PCR was done using 
pCAMBIA1303 specific primers 5 and 6 (Table 4.1) with the following cycle 
conditions: initial denaturing step for 5min at 94°C, followed by 35 cycles of 94°C 
(30sec), 45°C (40sec), 72°C (1min) and a final elongation of 10min at 72°C. PCR 
products were purified using a Wizard PCR clean-up system (Promega) and 
sequencing was done to confirm the  presence of inserts using the same plasmid 
specific primers. 86 
 
 
Figure 4.4 Plant transformation vector pCAMBIA1303 containing the PCV promoter 
and a CaMV35S-hygromycin resistance selectable marker gene. 
 
 
4.2.3 Plant transformation  
Binary vector pCAMBIA1303 containing  the PCV promoter and hygromycin 
selectable  gene  was introduced into competent A.tumefaciens  strain AGLO by 
electroporation as described in Chapter 2. Leaf disc transformation of tobacco plants 
was done using the method described in Chapter 2. Explants were incubated on co-
cultivation medium for two days and then transferred on SM1 medium conatining 
hygromycin (50mg/l). After 3-4 weeks, emerged shoots were transferred to rooting 
medium containing 50mg/l hygromycin.  
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4.2.4 Screening of putative transgenics 
Genomic DNA was extracted from plant leaves using the  method described in 
Chapter 2. PCR was carried out using primers 5 and 6 (Table 4.1) for confirmation of 
transgenics, the 156bp fragment was eluted from the gel using a Wizard SV gel clean 
up system (Promega) and sequencing was done as described in Chapter 2. Transgenic 
plantlets were then transferred to the PC2 glasshouse for further growth and analysis. 
4.2.5 Histochemical and fluorometric assays for GUS 
Explants from transgenic plants were analysed for the expression of the gus reporter 
gene as described in Chapter 2.  One day after histochemical staining for GUS, cells 
were destained in 70% ethanol to remove chlorophyll pigmentation. Fluorescence of 
4-MU was measured at 455nm using a Titertek Fluoroskan.  
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4.3 Results 
4.3.1 Amplification of the PCV promoter 
PCV genomic DNA was used to amplify the 156bp PCV promoter using specific 
primers with NcoI and HindIII restriction sites at the 5´ and 3´ ends respectively 
(Table 4.1). PCR products of 156bp were visualised on a 1.8% agarose gel (Figure 
4.5). PCR products were purified and subsequently cloned into pGEM-T (Promega). 
 
 
 
 
Figure 4.5 Agarose gel electrophoresis of the 156bp PCV promoter PCR product 
obtained using primers 1 and 2 (Table 4.1). Lane 1, 100bp DNA ladder; lane 2 and 3, 
PCV promoter; lane 4 negative control. 
 
 
4.3.2 Checking the presence of the PCV promoter in pGEM-T 
Following PCR amplification and purification the 156bp PCV promoter was cloned 
into pGEM-T. Plasmid DNA extracted from selected colonies was digested with NcoI 
and HindIII to confirm the nature of the insert, and PCR was done using primers 3 
1           2                  3                 4 
156bp 
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and 4 (Table 4.1) to visualise the expected 156bp fragment (Figure 4.6). The cloned 
fragment in pGEM-T was sequenced before sub-cloning into binary vector 
pCAMBIA 1303. 
In Figure 4.6, the size of PCV promoter in lanes 6 and 7 was slightly larger because it 
was amplified using primers in flanking regions with restriction sites.   
 
         
 
Figure 4.6  Agarose gel electrophoresis of pGEM-T with PCV promoter inserts 
digested with NcoI and HindIII and PCR of pGEM-T using primer 3 and 4 (Table 
4.1). Lane 1 and 9, 1Kb DNA ladder; Lane 2 and 4, unrestricted plasmid; Lane 3 and 
5, restricted plasmid; Lanes 6 and 7, PCR with PCV promoter specific primers, Lane 
8 negative control. 
 
 
4.3.3 Subcloning the 156bp PCV promoter sequence into a plant transformation 
vector  
The  desired  fragment  from pGEM-T  was excised from the gel, purified and sub 
cloned into the plant transformation vector pCAMBIA1303. CaMV35S promoter was 
replaced by 156bp PCV promoter which was cloned in frame with gus  gene. 
Recombinant pCAMBIA1303  with PCV promoter was digested with NcoI and 
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HindIII and 156bp promoter fragment was obtained (Figure 4.7). pCAMBIA1303 
with CaMV35S promoter was used as a control.  Sequencing was done prior to 
Agrobacterium mediated leaf disc transformation into tobacco plants. 
 
 
 
Figure 4.7 Restriction digestion of pCAMBIA 1303 with NcoI and HindIII. Lane 1, 
100bp DNA ladder; lane 2, pCAMBIA 1303 with 156bp PCV promoter; lane 3, 
pCAMBIA 1303 with CaMV35S promoter. 
 
 
4.3.4 Agrobacterium mediated tobacco transformation 
Plasmid DNA of binary constructs pCAMBIA1303-PCV promoter and 
pCAMBIA1303-CaMV35S (used as a positive control) were introduced into 
A.tumefaciens  strain AGLO using electroporation. Leaf disc transformation of 
tobacco was carried out and selection was done using hygromycin (50mg/L). 
Untransformed tobacco leaf discs were also grown on the same medium to use as a 
control; no shoots were developed on control leaf discs. Regenerated plants were 
analysed for the integration of the PCV promoter-gus fusion gene into plant genomes 
      1                      2                  3 
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by PCR. The selected plantlets were transferred to PC2 glasshouse for further 
analysis.  
The transgenic plant lines were named as follows: 
Circo means PCVpromoter-gus fusion gene line 
T0
4.3.5 Screening of transgenic plant lines 
 event number (1-9) 
35S-p1303 (CaMV35S-gus fusion gene) line 
PCR of DNA extracted by the CTAB method was done with primers 5 and 6 (Figure 
4.8). It confirmed the presence of the PCV promoter in transgenic N.tabacum plants. 
A total of 9 transgenic plants were confirmed after Agrobacterium  mediated 
transformation using PCR. 
 
 
 
 
 
Figure 4.8 Gel electrophoresis of PCR products for PCV promoter generated from 
genomic DNA of putative transgenics with primers 5 and 6 (Table 4.1).  Lanes 1-9, 
Clones circo1-9; lane 10, 35S-p1303; lane 11 negative control; lane 12, 1kb DNA 
ladder. 
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4.3.6 GUS analysis 
4.3.6.1 Histochemical analysis 
Leaves and roots of transgenic and control lines were stained with X-gluc, then 
destained, to find out if there was any expression of the gus gene. The leaves and 
roots of untransformed lines showed no blue staining, whereas a positive control line 
transformed with CaMV35S promoter (35S-GUS) showed blue staining (Figure 4.9, 
4.10). Gus histochemical analysis of 9 transformed lines also showed no obvious blue 
staining. 
 
 
 
 
Figure 4.9 X-gluc staining of leaves of transgenic plants (Circo1-9), pCAMBIA1303-
PCV promoter; pCAMBIA1303-CaMV 35S, positive control; Neg (Negative), 
untransformed line. 
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Figure 4.10 X-Gluc staining of roots of transgenic and control plants. (Circo1-9), 
pCAMBIA1303-PCV promoter; pCAMBIA1303-CaMV35S, positive control; Neg 
(Negative), untransformed line. 
 
 
4.3.6.2 Fluorometric analysis of transgenic plants with  PCV promoter-gus 
construct 
Although protein expression of the gus gene was not visualised histochemically, it 
was possible that there was a low level of expression. To test this possibility, 
fluorometric assays were done using MUG (non-fluorescent) as substrate which is 
converted to the fluorescent 4MU in the presence of GUS enzyme.  
GUS activity was quantified using the MUG assay for all 9 transgenic lines, a control 
line with 35S-GUS and an untransformed line. 
Standard curves were plotted for measuring protein concentration using BSA (Figure 
4.11) and for fluorescence by 4-MU (Figure 4.12). OD595 and fluorescence units of 94 
 
the samples were converted to protein and 4-MU concentration using these standard 
curves. The specific GUS activity was calculated per mg of protein value. 
 
 
Figure 4.11 Standard curve for protein assay using BSA (Bovine serum albumin). 
 
 
 
Figure 4.12 Standard curve for fluorescence of 4-MU (Fluorescence value in 
arbitrary units). 
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Enzyme activity was determined after every 30min for 180min for each sample (Fig 
4.13). It was observed that the activity of the gus enzyme assay was greatest over the 
first 30min, but the activity rapidly decreased with time. 
 
 
Figure 4.13 Time course of GUS activity in plant extracts. 
 
 
Therefore, the 4MU/min/mg protein value at T30 was taken to calculate the rate of 
GUS expression for leaves, roots and flowers of transgenic PCV promoter-Gus 
tobacco lines (Figure 4.14). 
 
Time (mins) 
4
 
M
U
/
m
i
n
/
m
g
 
p
r
o
t
e
i
n
s
 
 96 
 
 
Figure 4.14  Rate of GUS expression  (4MU/min/mg protein)  in leaves, roots and 
flowers of PCV promoter-GUS tobacco lines at T30. 
 
GUS histochemical analysis confirmed that 35S-p1303 had very high activity as 
expected (Figure  4.14). There was no significant difference in GUS expression 
between most of the transgenic lines (Circo1-9) and the untransformed control 
(negative). However, two of PCV promoter-GUS lines, Circo 5 and 7, showed a 
slightly higher level of GUS activity in leaves compared to the untransformed 
control.  Circo 3 lines showed some level of GUS activity in root extracts; and Circo 
7 line showed expression in flowers that is similar to the floral expression in 35S-
p1303. 
Error bars represent SEM. All 
assays were performed in triplicate. 
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4.4 Discussion 
The overall PCV genome shares substantial homology with plant nanoviruses such as 
BBTV, SCSV and CFDV. Nanoviruses were formerly classified as unassigned 
members of the Circoviridae and considered as plant circoviruses (Fauquet and 
Mayo, 2001). The PCV rep gene promoter contains the TATA box which is essential 
for DNA-dependent RNA polymerase and putative stem loop sequence. It also 
overlaps the intergenic region and origin of replication (Mankertz and Hillenbrand, 
2002). Promoters from the various nanoviruses, such as BBTV (Dugdale  et al., 
1998), SCSV (Schunmann et al., 2003), CFDV (Rohde et al., 1995) were previously 
examined and found to be successful in driving transgene expression in plants.  
In this study, the PCV rep gene promoter was isolated and analysed as a potential 
candidate for expression of gene in plants so that it might be used for production of 
recombinant proteins. Isolation and identification of novel promoters is very 
important for basic studies as well as for application in plant metabolic engineering 
(Yoshida and Shinmyo, 2000). 
The  PCV promoter was successfully cloned into plant transformation vector 
pCAMBIA 1303 and transgenic tobacco plants were obtained. 
No  clear  evidence of GUS expression could be found in transformed plants (T0) 
having the PCV promoter using histochemical staining, whilst it was clearly present 
in transformed 35S-p1303 line (positive control). Therefore, the more sensitive and 
quantitative 4-methylumbelliferyl-glucouronide (MUG) assay of the GUS activity 
was carried out. 98 
 
GUS activity is a rate and was measured over a period of 3h. The time course clearly 
showed that activity of gus  (35S-p1303) decreases significantly after 30min 
incubation and was essentially inactive after 90min. Therefore, the tangent to the 
curve was drawn and the initial rate of the reaction at 30min was taken to compare 
GUS expression of different transgenic lines. 
 Both the histochemical and fluorometric GUS assays showed that 35S-p1303 lines 
expressed the uidA  gene in all tissues  analysed similar to results obtained with 
histochemical staining. It was clearly visible that leaves had more GUS activity 
followed by roots and flowers in 35S-p1303 lines. The untransformed control also 
had a little background level of activity. Untransformed tobacco lines do not contain 
endogenous GUS activity which is why Gus assay results are very sensitive, but care 
is needed in interpreting GUS assay results. Since bacterial contamination or some 
low  level gus activity (eg. minor side reaction of galactosidase) may give some 
apparent activity. 
 However, in transformed PCV promoter-GUS lines 5 and 7, there appeared to be 
some expression in leaf extracts, and perhaps also in root extracts of Circo 3. 
The results show that if the PCV promoter directs GUS expression it cannot be 
visualised clearly by histochemical staining. However, when the more sensitive and 
quantitative fluorometric assay was used, low-level of expression may have been 
present in some of the lines where GUS staining was not observable.  
Since the study of transgene expression was carried out in T0 plants due to time 
constraints, this might contribute to the absence or low level of GUS expression in 99 
 
transformed plants, as T0 lines are probably ‘hemizygous’. The next generation plants 
(T1) with two copies of inserts could be more useful in analysis of GUS expression.  
Gene silencing could be another reason for trangene inactivation. Because there is no 
well established method for gene targeting in plant cells, the transgene is usually 
inserted randomly into chromosomes of transgenic plants. If a transgene is stably 
integrated near inactive chromatin, transcriptional gene silencing (TGS) takes place 
due to inactivation of transgene transcription. This phenomenon is referred to as 
position-effect variation (Bhattacharyya et al., 1994, Peach and Velten, 1991). TGS 
can also cause DNA methylation of the promoter region and changes in chromatin 
structure (Ye and Signer, 1996).  
In comparing the PCV and SCSV S1 and S4 promoters by aligning their nucleotide 
sequences, it is evident that there are some regions of homology, but also some 
substantial differences in sequence (Figure 4.15). In particular, the plant promoters 
appear to be larger than the PCV promoter. These differences may also contribute to 
absence or low level of expression of the linked gus gene in plants. 
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Figure 4.15 Comparison/alignment of PCV promoter with SCSV S1 and S4 promoter 
using MultiAlin. Note the low percentage of homology (~35%) between the PCV and 
plant nanovirus promoters. 
 
Although the expression of the PCV promoter in plants was absent or low, it might be 
increased by some modifications such as adding specific sequences like G-box motifs 
(CACGTG). These elements are present in many strong viral promoters such as 
SCSV promoters, promoters from plant pathogens like CaMV35S and FMV (Figwort 
mosaic virus) 34S and in the OCS (Octopine synthase) promoter, and contribute to 
high level expression of these promoters (Schunmann  et al., 2003).  Transgene 
expression levels might also be improved by duplication of individual motifs as  been 
done in the CaMV35S and OCS promoter (Ellis et al., 1987).  
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Chapter 5 
General Discussion 
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5.1 Introduction 
There is considerable interest in the potential use of plants as recombinant bioreactors 
for inexpensive, large scale production of various heterologous proteins. However, as 
for any scale-up from research level production, there will be some technical issues 
(eg. Location, prevention of cross-pollination, scale-up of extraction) that must be 
overcome. Much work has been done on production of edible vaccines (Li et al., 
2006, Rigano et al., 2006, Aziz et al., 2005). It has been speculated that the presence 
of plant cell walls delays digestion of plant derived antigens, thus more antigen is 
absorbed and presented to gut associated lymphoid tissue (Ma et al., 2005).  
Although this expression system constitutes an interesting alternative to conventional 
methods, the main disadvantages are the low concentrations of expressed antigens, 
and the lack of a reliable way of predicting whether or not a particular DNA sequence 
will express protein at a reasonable level in plant cells and that protein if expressed 
will be stable. Levels of protein expression and protein stability in plants can be 
influenced by many factors - these include transgene copy number, mRNA stability, 
modification of protein product and final compartmentalization in the plants (Koziel 
et al., 1996, Outchkourov et al., 2003, Gallie, 1998, Ziegelhoffer et al., 2001). Strong 
promoters and codon optimisation  (Rouwendal  et al., 1997, Ashraf  et al., 2005, 
Karasev et al., 2005, Yadava and Ockenhouse, 2003, Gustafsson et al., 2004) have 
been reported in many cases to overcome transcriptional and translational limitations. 
However, limited information is available regarding various post translational 
processes involved in the accumulation of mature proteins and their complete 
function (Dai et al., 2005). 103 
 
The main aim of this project was to generate transgenic plants of tobacco which can 
synthesise antigens (CA-Tat and SU) of JDV and to study the stability and level of 
production of these antigens in plants. 
An additional aim was to check whether or not a PCV promoter fused with a gus 
reporter gene, if introduced into plants, was expressed. 
5.2 Summary of findings 
JDV CA-Tat and SU genes were selected as potential candidates for producing 
antigens in plants. Both of these genes were successfully cloned into plant 
transformation vector JFH2 and transformed into tobacco plants using A.tumefaciens. 
This resulted in the successful generation of T0 and T1 
This may be the result of many factors: for example, there is good evidence that 
differences in codon usage between  plants and animals can  affect the level of 
expression of heterologous proteins in plant cells. Codon usage (frequency/thousand) 
analysed for JDV and N.tabacum is presented in Table 5.1. It can be seen that there 
are differences in codon preference for many amino acids: for Ala, GCC is preferred 
in JDV, whilst GCT is preferred in N.tabacum. For Ile, ATA in JDV and ATT in 
tobacco lines containing the 
desired CA-Tat and SU expression constructs, but despite being successfully 
transcribed into mRNA as confirmed by RT-PCR, no protein expression was detected 
for either of the antigens analysed by western blotting and dot blots. This means that 
either  the  mRNA was not successfully translated or that  the protein was rapidly 
degraded after synthesis or low levels of protein expressed that were below detection 
limit of the assay. 104 
 
plant, likewise for Lys, AAA is the preferred codon in JDV over AAG, and for Val, 
GTG in JDV and GTT in N.tabacum.  
Changes in these codons in the expression construct to reflect plant codon usage 
could make  the production  of JDV antigens more  efficient in tobacco.  Codon 
modification from microbial to plant preferred codons has been used in a number of 
systems. Optimisation of gene sequences for plant codon usage has improved the 
expression of various antigens such as E.coli heat labile enterotoxin subunit B (LT-B) 
(Mason  et al., 1998)  and cholera toxin subunit B (CT-B)  (Kang  et al., 2004). 
Accumulation of LT-B was improved from 5 to 40 fold when a codon optimised gene 
was used instead of an unmodified gene (Mason et al., 1998). 
Table 5.1 Codon usage (frequency/thousand) for JDV and N.tabacum  
 
Amino acid  Codon  JDV (frequency/thousand)  N.tabacum 
(frequency/thousand) 
Ala  GCG  3.88  5.8 
  GCA  15.91  23.0 
  GCT  18.63  32.0* 
  GCC  35.0*  12.6 
Cys  TGT  10.87  9.9 
  TGC  8.93  7.6 
Asp  GAT  21.73  36.7 
  GAC  19.01  16.9 
Glu  GAG  26.39  29.1 
  GAA  38.80  35.0 
Phe  TTT  16.69  24.4 
  TTC  13.58  17.8 
Gly  GGG  26.0  10.5 
  GGA  33.76  23.5 
  GGT  10.48  23.1 
  GGC  14.36  11.4 
His  CAT  10.87  13.3 
  CAC  11.64  8.6 
Ile  ATA  27.94*  13.9 
  ATT  18.63  27.3* 
  ATC  13.97  13.7 
Lys  AAG  22.12  33.9* 
  AAA  38.03*  32.3 
Leu  TTG  14.75  21.9 
  TTA  13.58  12.5 
  CTG  15.91  10.4 
  CTA  18.24*  9.2 105 
 
Amino acid  Codon  JDV (frequency/thousand)  N.tabacum 
(frequency/thousand) 
  CTT  9.31  12.2 
  CTC  10.87  23.7* 
Asn  AAT  22.89  27.4 
  AAC  14.36  18.6 
Pro  CCG  8.93  4.9 
  CCA  20.57  20.0 
  CCT  15.13  18.8 
  CCC  17.46  6.7 
Gln  CAG  20.95  15.5 
  CAA  26.39  21.3 
Arg  AGG  19.79  12.5 
  AGA  27.94  15.5 
  CGG  7.76  3.7 
  CGA  5.43  5.1 
  CGT  3.49  7.4 
  CGC  3.88  4.0 
Ser  AGT  12.42  13.3 
  AGC  13.97*  10.0 
  TCG  1.55  5.4 
  TCA  7.76  17.7 
  TCT  6.60  20.3* 
  TCC  7.76  10.7 
Thr  ACG  3.10  4.6 
  ACA  24.45*  17.4 
  ACT  13.97  20.8* 
  ACC  13.58  10.0 
Val  GTG  22.51*  16.6 
  GTA  21.34  11.2 
  GTT  12.42  27.0* 
  GTC  12.03  11.4 
Trp  TGG  27.55  11.6 
Tyr  TAT  16.69  17.8 
  TAC  13.58  13.5 
*indicates significant differences in codon preferences 
Another important factor controlling the yield of recombinant proteins is subcellular 
targeting, which affects the folding, assembly and post-translational modification. In 
the absence of targeting information, proteins in the the endomembrane system are 
secreted to the apoplasts, where they might be retained or secreted into the 
environment (Ma et al., 2003). It is possible that the protein was insoluble or bound 
to membranes, and so was not extracted and detected. 
There are differences in post-translational modifications, specifically covalent linkage 
of sugar chains in the formation of mature proteins in plants and animals (Saint-Jore-106 
 
Dupas  et al., 2007)  and these differences can have dramatic effects on the 
accumulation of a recombinant protein. If proteins are not properly cleaved, 
proproteins will accumulate instead of mature proteins (Bakker et al., 2001) and the 
differences between plant and animal glycan could make plant-derived proteins more 
susceptible to protease activity. 
High mRNA levels do not necessarily translate into high levels of protein. Lack of 
correlation between foreign mRNA transcript levels and protein production has been 
observed in many cases in transgenic plants (Ohtani et al., 1991, Outchkourov et al., 
2003).  Transgene silencing  can  also  affect  both transcription and  translation. 
Silencing encompasses a group of epigenetic phenomena that can reduce transgene 
expression at either the transcriptional or the post-transcriptional level (Twyman et 
al., 2003). The former may involve methylation of transgenes, whereas the latter may 
involve RNA interference and gene silencing, especially if more than one copy of a 
transgene is present. 
The amount of heterologous protein produced in plant cells is the result of a balance 
between protein synthesis  and protein loss. Protein stability is  a key  factor  in 
regulating the accumulation of heterologous proteins  in  transgenic plants and in 
determining the overall yield of foreign proteins  in plant cells. There are several 
examples in which accumulation of foreign protein in plants is limited by proteolytic 
degradation of a  heterologous protein (Dolja  et al., 1998, Stevens  et al., 2000). 
Proteolytic degradation of heterologous proteins in plant cells could be reduced by 
removal or replacement of proteolytic sites from the recombinant proteins, silencing 107 
 
of the genes encoding the major proteases in plant cells or by targeting the protein to 
the endoplasmic reticulum (Miao et al., 2008).  
If CA-Tat and SU protein can be successfully  expressed in tobacco plants, these 
could be used following purification, as a vaccine antigen, or produced in another 
feed plant such as alfalfa (Medicago sativa) which could be ingested intact by cattle. 
Plant derived vaccines can be delivered in many different ways. Direct feeding of 
intact plant  material  offers  many advantages, including the ability to stimulate 
systemic as well as mucosal immune responses, facilitated by large scale production 
and delivery of proteins  to gut-associated lymph tissue. However, the  main 
disadvantage of direct feeding of a plant tissue expressing antigens is the dosage 
levels  of recombinant vaccine  which are not controlled.  This  drawback could be 
overcome either by using freeze dried/pelleted plant tissue or, after purification by 
injecting  the  purified antigen protein preparation  using a standard vaccination 
protocol. For use as pelleted/freeze dried vaccines, these could be grown easily in an 
animal feed plant such as  alfalfa or maize, although the requirement is that this 
material is strictly kept away from any other plants grown for animal and human 
foods. Freeze dried plant tissue could be used to concentrate and stabilize the antigen 
in a dried form that could also be stored at room temperature. 
Further advances in obtaining successful protein expression could be helped with the 
use of a more sensitive assay which could distinguish even very small differences in 
expressed protein, or by using a stronger promoter.  108 
 
Once an increased level of antigen production in plants has been achieved, one of the 
final issues to be overcome are those related to containment of the transgenic plants 
to prevent gene transfer to conventional crops during plant growth and commercial 
production. Transgenic plants used for molecular farming of vaccines or therapeutic 
should be maintained in a glasshouse or other contained facility under controlled 
environmental conditions,  or  perhaps isolated  in irrigated desert plots. Specific 
treatments to prevent pollen escape in the field, such as covering of flowers and 
fruits, should be applied to ensure isolation from food crops (Tackaberry et al., 2003).  
It is critical to ensure complete segregation and isolation of any such recombinant 
material. Planting transgenic plants at a different time than the nearest related food 
plants could also be used so that their pollination times do not overlap and planting of 
non-transgenic border rows around the transgenic crop  could also  enhance 
containment of pollen. Strict handling chain identity preservation procedures are 
required for any  production, harvesting and processing of plants producing 
pharmaceuticals. 
The secondary aim of the work was testing the possibility that the full length PCV 
rep  gene  promoter could also act as a novel IP free, plant promoter, was also 
completed. The results suggested that the promoter sequence tested showed very low 
if any, promoter activity in plant cells. The reason for its use was that so far no animal 
virus promoter has been shown to work in plant cells and most constitutive plant 
promoters are derived from plant DNA viruses (eg the closely related Nanoviruses, or 
Caulimoviruses such as CaMV35S). Those currently identified are all under IP 
protection, so PCV might provide a novel plant acting promoter. The results indicate 109 
 
that more work needs to be undertaken to convert the PCV promoter to enable higher 
transcription of linked genes in plants. Alignment of the PCV promoter with plant 
nanovirus promoters (Figure 4.15) to identify sequences that could be modified in the 
PCV sequence to drive plant expression indicate that plant promoters appear to be 
larger that the PCV promoter and this may account for the very low expression found. 
To extend this work, it would be possible to design a novel hybrid promoter from the 
PCV promoter domains by combining them with a minimal CaMV35S promoter, or 
incorporating some plant specific sequences in the PCV promoter. 
In conclusion, with some additional work that incorporates the changes suggested, we 
could expect that a system in which JDV antigen is successfully produced in plants 
will be successful, and that a suitably modified PCV promoter could drive expression 
of linked gene in plants. 
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